


Organization TC-1600 Bldg./Room Penner
U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231

IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

AN EQUAL OPPORTUNITY EMPLOYER



Handwritten signature: D. J. [unclear]

Handwritten signature: [unclear]

IPRITON INC.
750 B. ROAD
SILVER CITY, CA 94061

RECEIVED
APR 02 2004
TECH CENTER 1600/2900

Organization TC-1600 Bldg./Room Dever
U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

AN EQUAL OPPORTUNITY EMPLOYER



Handwritten signature

Handwritten signature

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231

RECEIVED
APR 02 2004
TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/005,202	12/04/2001	Keith D. Allen	R-902	6809

7590 03/18/2004
DELTAGEN, INC.
740 Bay Road
Redwood City, CA 94063

EXAMINER

WILSON, MICHAEL C

ART UNIT	PAPER NUMBER
1632	

DATE MAILED: 03/18/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/005,202

Applicant(s)

ALLEN, KEITH D.

Examiner

Michael C. Wilson

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 July 2003.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-28 is/are pending in the application.
- 4a) Of the above claim(s) 1,2,13 and 26-28 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 3-12 and 14-25 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 06-03-02 6) ☐ Other:

DETAILED ACTION

Specification

New Fig. 3 and the amendment to the description of Fig. 3 have been entered.

The applications cited in the specification on pg 10, line 19, and pg 11, line 1, will need updated as necessary.

Election/Restrictions

Applicant's election without traverse of Group II, claims 3-12 and 14-25 is acknowledged.

The requirement is still deemed proper and is therefore made FINAL.

Claim 1, 2 and 26-28 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Claims 3-12 and 14-25 are under consideration in the instant office action.

Claim Objections

Claim 9 is objected to because it is dependent upon claim 1 which is not under consideration.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Art Unit: 1632

Claims 3-12 and 14-25 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific or substantial asserted utility or a well-established utility.

Claims 6, 7 and 14-24 are directed toward a transgenic animal having a disruption of a Kir5.1 gene, an inwardly rectifying potassium channel. Claims 10 and 25 are directed toward methods of using the mice to identify compounds. The art at the time of filing did not teach mice with a disruption in the Kir5.1 gene. However, the art at the time of filing taught mice with a disruption in GIRK2 (Kir3.2) are indistinguishable from wild-type mice, while *wv/wv* mice, having a single point mutation in the Kir3.2 gene, had extensive cerebellar granule cell death, dopaminergic neuronal loss in the substantia nigra, male infertility, and spontaneous seizures (Signorini, 1997, PNAS, Vol. 94, pg 923-927). Thus, different mutations in inwardly rectifying potassium channels caused different phenotypes. The specification teaches making Kir5.1 *-/-* mice having dwarfed body shape (pg 53, lines 21-22), decreased body weight, spleen weight and spleen:body weight ratio (pg 54, lines 54), and increased startle response (pg 55, lines 8-11).

The mouse claimed does not have a specific utility. The specification suggests using the mice as a model of disease but does not disclose a specific disease in humans linked to a disruption in Kir5.1 (pg 18, lines 8-9; pg 19, lines 21-23). The specification suggests using the mice to compounds that alter a physiological response in the mice (pg 19, lines 5-20). The specification does not teach a disruption in Kir5.1 correlates to any specific disease or physiological response in humans, specifically

Art Unit: 1632

dwarfism, decreased spleen weight, or anxiety as claimed. Using the mice claimed to identify compounds is not specific to the mouse claimed because wild-type mice may be used to identify such compounds. In fact, any mouse can be used to find compounds that increase body weight, increase spleen weight or decrease the startle response. The specification teaches the "open field test" is generic to the hearing processing, sensory and motor processing, global sensory processing and motor abnormalities (pg 54, lines 20-25) as well as sensorimotor processing, attention, anxiety and thought disturbance (pg 54, lines 26-30); therefore, the "open field test" is not specific to any disease. Thus, using the mouse claimed to identify compounds is not specific to that mouse, and the mouse claimed does not have a use that is specific to any disease in humans.

The mouse claimed does not have a substantial utility. Claims 10-11, step c) require administering compounds to the mice and determining whether Kir5.1 gene expression is modulated. Compounds that modulate Kir5.1 expression cannot be found using the mice disclosed because Kir5.1 is not expressed in the mice. Claim 24 requires using identifying an agent that ameliorates a phenotype associated with Kir5.1 by administering compounds to the mice and determining whether a phenotype is ameliorated; however, the specification does not identify any compounds that alter physiological responses using the mice. Therefore, using the mouse to identify compounds is not substantial.

Claim 9 is included because it is directed toward making the mouse, which lacks utility for reasons above. Claims 3-5, 8 and 15, directed toward cells having a disrupted

Art Unit: 1632

Kir5.1 gene, and claims 11-12, directed toward using the cells to test compounds, are included because the cells lack a specific and substantial utility for the reasons above.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 3-12 and 14-25 are also rejected under 35 U.S.C. 112, first paragraph.

Specifically, since the claimed invention is not supported by either a specific or substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

In addition, the specification does not reasonably provide enablement for any animal, Kir5.1 gene, phenotype, cell, disruption, method of making a transgenic or method of using a transgenic as broadly claimed.

Claims 6, 7 and 14-24 are directed toward a transgenic animal having a disruption of a Kir5.1 gene. Claims 10 and 25 are directed toward methods of using the mice to identify compounds. The art at the time of filing did not teach mice with a disruption in the Kir5.1 gene. However, the art at the time of filing taught mice with a disruption in GIRK2 (Kir3.2) are indistinguishable from wild-type mice while *wv/wv* mice, having a single point mutation in the Kir3.2 gene, had extensive cerebellar granule cell death, dopaminergic neuronal loss in the substantia nigra, male infertility, and

Art Unit: 1632

spontaneous seizures (Signorini, 1997, PNAS, Vol. 94, pg 923-927). Thus, different mutations in inwardly rectifying potassium channels caused different results.

The specification teaches making Kir5.1 $-/-$ mice having dwarfed body shape (pg 53, lines 21-22), decreased body weight, spleen weight and spleen:body weight ratio (pg 54, lines 54), and increased startle response (pg 55, lines 8-11).

The specification does not enable making or using a transgenic with a wild-type phenotype as encompassed by the claims. The transgenics throughout many of the claims do not recite any phenotype and may, therefore, have any phenotype including wild-type phenotype. The specification does not provide any use for a transgenic having a disruption in Kir5.1 that has a wild-type phenotype.

The specification does not teach how to make any cell having a disruption in a Kir5.1 (claims 3-5). Specifically, claims 4-5 encompass mice and rat cells. "Murine" encompasses mice and rats (<http://www.m-w.com/cgi-bin/dictionary?book=Dictionary&va=murine>). The only means of making a cell with a disruption in Kir5.1 taught in the specification is by using mouse embryonic stem cell technology. The state of the art at the time of filing was such that embryonic stem (ES) cell technology had only been successful in mice. Wagner (May 1995, Clin. and Experimental Hypertension, Vol. 17, pages 593-605) and Mullins (1996, J. Clin. Invest., Vol. 98, pages S37-S40) taught germline transmission of ES cells has not been demonstrated in species other than mice and the growth of ES cells from species other than mice is unreliable. Wall (1996, Theriogenology, Vol. 45, pg 57-68) taught transgene expression and the physiological result of such expression in livestock was

Art Unit: 1632

not always accurately predicted in transgenic mice (page 62, line 7). The specification fails to provide sufficient guidance to make transgenics other than mice by teaching obtaining ES cells in species other than mice. The specification does not teach the nucleic acid sequence of the Kir5.1 gene in non-mice, non-human species or correlate the Kir5.1 gene in mice to the Kir5.1 gene in other species. The specification does not teach how to make knockout animals other than mice or correlate making knockout mice to other species. Therefore, the specification does not provide adequate guidance for one of skill in the art to make cells having a disruption in Kir5.1 in any species other than mice.

Claim 9 is directed toward a method of making a transgenic mouse having a disruption in Kir5.1 using a cell having a construct with two sequences of Kir5.1, introducing the cell into a blastocyst, implanting the blastocyst into a pseudopregnant mouse which gives birth to chimeric mice, and breeding the chimeric mouse to produce the transgenic mouse. The claim does not require using mouse cells or an embryonic stem cell, which is considered essential to the invention. A mouse ES cell is the only type of cell taught in the specification that can be introduced into a blastocyst and result in a chimeric mouse as claimed. The claim does not require the mouse have a non-wild type phenotype, which is required for reasons cited above. Given the unpredictability in the art taken with the guidance provided in the specification, the cell in a) should be a mouse ES cell, the blastocyst in b) should be a mouse blastocyst, and the transgenic mouse produced should have a genome comprising a homozygous disruption in Kir5.1, wherein said mouse lacks functional Kir5.1.

Claims 10-12 are directed toward methods of screening compounds using a cell or mouse having a disruption in a Kir5.1 gene. Step (c) requires determining whether the expression or function of Kir5.1 is modulated but the mice and cells do not express Kir5.1. The specification does not teach how to determine Kir5.1 expression in mice having a disruption in Kir5.1. While the specification teaches transgenics expressing LacZ, the specification does not teach how to use such mice in an assay to determine whether a compound modulates Kir5.1. Without such a disclosure, the specification does not provide adequate guidance for one of skill to use the mouse disclosed to determine compounds that modulate Kir5.1 expression or function.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 10-12, 14, 15, 17, 18, 21, 24 and 25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 10-11 are indefinite because the mice do not express Kir5.1; therefore, Kir5.1 expression cannot be tested as claimed.

Claim 14 is indefinite because the metes and bounds of what applicants consider "significant" expression cannot be determined.

Claims 17 and 18 are indefinite because "increased anxiety" and "stimulus processing disorder" do not further limit "increased acoustic startle response" in parent claim 16. If claims 17 and 18 do further limit the acoustic startle response or the function of the mouse, it cannot be determined how. The startle test is generic

Art Unit: 1632

numerous nervous, muscle and cognitive functions (pg 54, lines 20-30). The limitations do not further limit a characteristic of the mouse because all mice having increased acoustic startle response are considered to have increased anxiety or stimulus processing disorder as claimed.

Claim 21 does not further limit claim 20 because all mice having dwarfism have decreased body weight.

Claim 25 is indefinite because phenotypes "associated" with a disruption in Kir5.1 cannot be determined. While the mice having a disruption in Kir5.1 have dwarfism and increased response to the startle test, it cannot be determined if those phenotypes are "associated" with Kir5.1 in humans. It is unclear if mice having a disruption in a gene mapped to the distal region of mouse chromosome 11 (see Mouri pg 182, Fig. 1, and col. 2, "additional comments") are "associated" with a disruption in Kir5.1.

Claim 25 is indefinite because it does not recite how to determine whether an agent ameliorates a phenotype and neither does the specification. It is unclear what controls are required and how such a determination is made. It is also unclear why a mouse having a disruption in Kir5.1 is required because any mouse can be used to determine whether a compound increases body size, body weight, spleen weight or spleen weight:body weight ratio.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1632

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 3-9 and 14 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Signorini (1997, PNAS, Vol. 94, pg 923-927) in view of Mouri (Genomics, 1998, Vol. 54, pg 181-182).

Signorini taught making a transgenic mouse having a disruption in an inward rectifier protein (GIRK2/Kir3.2) (pg 924, col. 2, 2nd ¶). Signorini did not teach disrupting the Kir5.1 gene in the mice.

However, Mouri taught the nucleic acid sequence of the mouse Kir5.1 gene (GenBank Accession No: AB016197).

Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to make a transgenic mouse having a disruption in an inward rectifier protein as taught by Signorini wherein the inward rectifier protein was Kir5.1 as taught by Mouri. One of ordinary skill in the art at the time the invention was made would have been motivated to disrupt the Kir5.1 gene instead of the Kir3.2 gene to determine the function of Kir5.1 in the brain *in vivo*.

Thus, Applicants' claimed invention, as a whole is prima facie obvious in the absence of evidence to the contrary.

Conclusion

No claim is allowed.

Art Unit: 1632

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-0120.

Questions of a general nature relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

If attempts to reach the examiner, patent analyst or Group receptionist are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051.

The official fax number for this Group is (703) 872-9306.

Michael C. Wilson

INFORMATION DISCLOSURE CITATION FORM PTO-1449						Atty. Docket No.: R-902		Serial No.: 10/005,202	
						Inventor: ALLEN			
						Filing Date: December 4, 2001		Group Art Unit: 1632	
U.S. PATENT DOCUMENTS									
EXAMINER'S INITIALS	REF.	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
				COPY OF PAPERS ORIGINALLY FILED					
FOREIGN PATENT DOCUMENTS									
EXAMINER'S INITIALS	REF.	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation		
							Yes	No	
OTHER DOCUMENTS									
EXAMINER'S INITIALS	REF.	(Including Author, Title, Date, Pertinent Pages, Etc.)							
uuu	AA	T. Mouri et al., "ASSIGNMENT OF MOUSE INWARDLY RECTIFYING POTASSIUM CHANNEL Kcnj16 TO THE DISTAL REGION OF MOUSE CHROMOSOME 11," Genomics, Vol. 54, September 1998, pp. 181-182							
uuu	AB	J. Leaney et al., "THE ROLE OF MEMBERS OF THE PERTUSSIS TOXIN-SENSITIVE FAMILY OF G PROTEINS IN COUPLING RECEPTORS TO THE ACTIVATION OF THE G PROTEIN-GATED INWARDLY RECTIFYING POTASSIUM CHANNEL," Proc. Natl. Acad. Sci., Vol. 97, No. 10, May 9, 2000, pp. 5651-5656							
EXAMINER:				DATE CONSIDERED: 10-17-03					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformity and not considered. Include copy of this form with next communication to applicant.

Notice of References Cited	Application/Control No. 10/005,202	Applicant(s)/Patent Under Reexamination ALLEN, KEITH D.	
	Examiner Michael C. Wilson	Art Unit 1632	Page 1 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	<input checked="" type="checkbox"/> U	Signorini, 1997, PNAS, Vol. 94, pg 923-927
	<input type="checkbox"/> V	Wagner (May 1995, Clin. and Experimental Hypertension, Vol. 17, pages 593-605
	<input checked="" type="checkbox"/> W	Mullins (1996, J. Clin. Invest., Vol. 98, pages S37-S40
	<input checked="" type="checkbox"/> A	Wall (1996, Theriogenology, Vol. 45, pg 57-68

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

10/005,202

Applicant(s)/Patent Under
Reexamination
ALLEN, KEITH D.

Examiner

Michael C. Wilson

Art Unit

1632

Page 2 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
X	U	Mouri (Genomics, 1998, Vol. 54, pg 181-182
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Normal cerebellar development but susceptibility to seizures in mice lacking G protein-coupled, inwardly rectifying K⁺ channel GIRK2

(GIRK1/embryonic stem cells/genetics/weaver/cerebellum)

STEFANO SIGNORINI*†, Y. JOYCE LIAO‡, STEPHEN A. DUNCAN*, LILY Y. JAN*§, AND MARKUS STOFFEL*†¶

Laboratories of *Metabolic Diseases and †Molecular Cell Biology, Rockefeller University, New York, NY 10021; and ‡Departments of Physiology and Biochemistry and §Howard Hughes Medical Institute, University of San Francisco, San Francisco, CA 94143-0724

Contributed by Lily Y. Jan, November 21, 1996

ABSTRACT G protein-gated, inwardly rectifying K⁺ channels (GIRK) are effectors of G protein-coupled receptors for neurotransmitters and hormones and may play an important role in the regulation of neuronal excitability. GIRK channels may be important in neurodevelopment, as suggested by the recent finding that a point mutation in the pore region of GIRK2 (G156S) is responsible for the weaver (*wv*) phenotype. The GIRK2 G156S gene gives rise to channels that exhibit a loss of K⁺ selectivity and may also exert dominant-negative effects on G_{βγ}-activated K⁺ currents. To investigate the physiological role of GIRK2, we generated mutant mice lacking GIRK2. Unlike *wv/wv* mutant mice, GIRK2 ^{-/-} mice are morphologically indistinguishable from wild-type mice, suggesting that the *wv* phenotype is likely due to abnormal GIRK2 function. Like *wv/wv* mice, GIRK2 ^{-/-} mice have much reduced GIRK1 expression in the brain. They also develop spontaneous seizures and are more susceptible to pharmacologically induced seizures using a γ -aminobutyric acid antagonist. Moreover, *wv/-* mice exhibit much milder cerebellar abnormalities than *wv/wv* mice, indicating a dosage effect of the GIRK2 G156S mutation. Our results indicate that the weaver phenotypes arise from a gain-of-function mutation of GIRK2 and that GIRK1 and GIRK2 are important mediators of neuronal excitability *in vivo*.

G protein-gated, inwardly rectifying K⁺ channels (GIRK) are regulated by neurotransmitters and hormones through G protein-coupled receptors (1–3). GIRK channels are believed to determine neuronal membrane excitability by selectively permitting the flux of K⁺ ions near the resting membrane potential (4–7). The weaver mouse, a neurological mutant characterized by extensive cerebellar granule cell death during development (8–10), age-dependent dopaminergic neuronal loss in the substantia nigra (11, 12), male infertility (13), and spontaneous seizures (14), carries a G156S point mutation in the pore-forming region H5 of GIRK2 (15). This mutation leads to a loss of K⁺ selectivity of homomeric GIRK2 channels and strongly reduces heteromeric GIRK1/GIRK2 channel function (16–18). Electrophysiological recordings from weaver and wild-type cerebellar granular cells have yielded conflicting reports, supporting either a loss of K⁺ selectivity (16) or a loss of channel function (19). To study the physiological effects of GIRK2 *in vivo* and to address the question whether the phenotypic defects in the weaver mouse are due to gain-of-function effects such as the loss of K⁺ selectivity or due to loss-of-function or dominant-negative effects on GIRK1/

GIRK2 heteromultimeric channels, we have generated GIRK2-deficient mice and compared them to mice carrying one or two copies of the *wv* allele but no wild-type GIRK2 gene.

MATERIALS AND METHODS

Genomic Cloning and Construction of a Targeting Vector. Genomic clones containing the murine GIRK2 gene were isolated from a λ FIX II murine 129/Sv genomic library (Stratagene) by screening the library using the full-length hamster GIRK2 cDNA as a probe (20). Two identical phage clones containing the entire murine GIRK2 gene were identified, and three exons containing the entire open reading frame were mapped. To generate the GIRK2 targeting vector pPNT-76, an \approx 8-kb *Eco*RI fragment containing exon 1 and part of exon 2 was inserted into the targeting vector pPNT (21) such that its 3' end was adjacent to the PGK promoter upstream of the neomycin gene. The 3' end of the targeting construct was generated from the same GIRK2 genomic clone and contained a 0.47-kb *Bgl*II-*Xba*I fragment that was inserted into the exon 2 *Eco*RI/*Bgl*II deletion and included sequences from exon and intron 2 (Fig. 1A). The targeting vector was linearized by *Nof*I and electroporated into R1 embryonic stem (ES) cells at 200 V and 800 mF. Stable colonies were grown under double selection in 350 μ g/ml G418 and 0.2 mM gancyclovir in ES cell medium (22). By Southern blotting, 150 colonies were analyzed for homologous recombination. One clone (G2) was identified by the presence of a 1.9-kb *Bgl*II band and was microinjected into blastocysts to generate GIRK2-deficient mice (Fig. 1B).

Western Blot Analysis. Mouse brain membrane (50 μ g), prepared as described (23, 24), was solubilized in 2% SDS/sample buffer (125 mM Tris, pH 6.8/20% glycerol/5% 2-mercaptoethanol) and loaded onto each lane. Western blots were probed with 1 μ g/ml affinity-purified rabbit polyclonal antibodies against the N terminus of GIRK2 or GIRK1 or against the C terminus of GIRK1 (23). Donkey anti-rabbit-horseradish peroxidase was used as secondary antibody at 1:5000 dilution. The blots were developed with enhanced chemiluminescence reagents (Amersham) and exposed to Hyperfilm-ECL (Amersham).

Immunohistochemistry. Mice were perfused intracardially with 4% formaldehyde and 0.1% glutaraldehyde in PBS (pH 7.4). Brains were dissected and postfixed overnight at 4°C. Fifty-micrometer vibratome sections were collected in 0.1 M Tris (pH 7.6); blocked with 2% H₂O₂; washed in 50 mM Tris, pH 7.5/100 mM NaCl/0.1% Triton X-100 (TBST); and then blocked in 4% normal goat serum and 3% BSA in TBST.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Copyright © 1997 by THE NATIONAL ACADEMY OF SCIENCES OF THE USA
0027-8424/97/94923-5\$2.00/0
PNAS is available online at <http://www.pnas.org>.

Abbreviations: PTZ, pentylenetetrazol; ES cells, embryonic stem cells; RT, reverse transcriptase; TH, tyrosine hydroxylase.

¶To whom reprint requests should be addressed at: Laboratory of Metabolic Diseases, Rockefeller University, New York, NY 10021.




FIG. 1. (A) Targeted disruption of the mouse *Girk2* gene in ES cells and mice. The genomic structure and restriction map of the mouse *Girk2* gene locus and targeting vectors pNT-76 used to disrupt the *Girk2* gene are shown. Shaded boxes represent coding sequences of the exons (boxes). The probe 3' of the deletion is used for Southern blot analysis and shown as an open bar. B, *Bgl*II; A, *Acc*I; E, *Eco*RI; X, *Xba*I. (B) Southern analysis of transfected ES cells. Lanes: 1, targeted clone containing the targeted allele, as assessed by the presence of an additional 1.9-kb *Bgl*II fragment; 2, parental clone containing the normal 1.6-kb fragment; 3-9, genotypes from tail biopsies of *Girk2* $+/+$, $+/-$, and $-/-$ mice. (C) Reverse transcriptase (RT)-PCR analysis from brain mRNA of *Girk2* $+/+$, $+/-$, and $-/-$ mice. (Upper) *Girk2* wild-type and mutant alleles are shown with the position of oligonucleotides used as PCR primers. D, deleted region into which the pgk-neomycin resistance cassette was inserted. No primer-pair amplified products in the absence of reverse transcrip-

Rabbit antibodies were affinity-purified, and sections were incubated in 1-2 μ g/ml primary antibody overnight (23, 24). Monoclonal antibodies against tyrosine hydroxylase (TH; Pel-Freez Biologicals) were used at 1:1000. Biotinylated donkey anti-rabbit or anti-mouse IgG Fab (The Jackson Laboratory) were used at 1:200, and sections were developed with the ABC kit (Vector Laboratories) and diaminobenzidine.

Induction of Seizures Using Pentylentetrazole (PTZ). PTZ (Sigma) was dissolved in PBS and injected i.p. at a dose of 50 mg/kg in \sim 0.1 ml. Animals were housed in a room with controlled light/dark cycle (12 hr light/12 hr dark) and temperature (23°C). All experiments were performed between 11 a.m. and 1 p.m. Animals were injected and observed without prior knowledge of their genotype. Each mouse was placed in a transparent cage and observed for 30 min after injection. All mice were littermates between 10 and 14 weeks of age and weighed \geq 20 g.

RESULTS AND DISCUSSION

Generation of *Girk2* Null Mice. The *Girk2* gene was disrupted in ES cells by homologous recombination using a targeting vector in which exon 2 was disrupted and partially deleted by a pgk-neomycin resistance cassette (Fig. 1A). One ES cell clone that carried the targeted allele was used to generate chimeric male animals that passed the mutant allele to their offspring. *Girk2* $+/-$ mice were indistinguishable from wild-type mice and were inbred to produce *Girk2* $-/-$ mice (Fig. 1B). No normal *Girk2* mRNA could be detected in brains of adult *Girk2* $-/-$ mice by RT-PCR analysis, but a truncated *Girk2* mRNA was present (Fig. 1C). No *Girk2* immunoreactivity was detectable using antibodies against either the N terminus or C terminus of *Girk2* (Figs. 2A and 3A and B; data not shown). We conclude, therefore, that we have generated *Girk2* null mice.

Down-Regulation of *Girk1* Protein in *Girk2* Null Mice. *Girk2* $-/-$ mice are born at the expected frequency and are viable. Given that *Girk2* and *Girk1* have partly overlapping temporal and spatial expression patterns and are known to form functional heteromultimers *in vitro* (16-18, 25-28) and *in vivo* (24), we examined the expression of *Girk1* and other related inward rectifier channels by using affinity-purified polyclonal antibodies against *Girk1*, *Irkl*, and *Girk4* in Western blot and immunohistochemical studies of *Girk2* $+/+$, $+/-$, and $-/-$ mice. Immunoblot analysis showed that *Girk1* levels were reduced in brain membranes of *Girk2* $+/-$ mice and nearly undetectable in $-/-$ mice, whereas *Irkl* protein levels remained constant in mice of all three genotypes (Fig. 2A). RT-PCR analysis showed that *Girk1*, *Girk4*, and *Irkl* mRNA were similar in all animals, suggesting that the down-regulation of *Girk1* in *Girk2* $-/-$ mice occurred posttranscriptionally (Fig. 2B). Immunohistochemical analysis showed dramatic reduction of *Girk1* immunoreactivity in many brain regions in *Girk2* $-/-$ mice, whereas *Irkl* and *Girk4* immunoreactivities were normal in these *Girk2* mutants (Fig. 3A and B; data not shown). The extent of reduction in *Girk1* varied with the brain regions; expression of *Girk1* in the cerebral cortex and hippocampus was virtually undetectable, whereas in the cerebellum, significant amounts of *Girk1* remained in the granule cell layer (Fig. 3A and B). The reduction of *Girk1* protein levels throughout the brain suggests that a majority of *Girk1* proteins in the brain interact with *Girk2*, and in the absence

tase. Each sample started with an equal amount of cDNAs. A 5'-truncated mRNA terminating in pgk-neomycin can be detected by PCR at reduced levels in $+/-$ and $-/-$ animals. The sequences of the oligonucleotide used are available upon request.




FIG. 2. (A) Western blots of membrane prepared from GIRK2 $+/+$, $+/-$, and $-/-$ mouse brains show that both GIRK2 and GIRK1 protein levels are reduced in the GIRK2 knockout mice. (B) RT-PCR showing equal mRNA expression of GIRK1 in $+/+$, $+/-$, and $-/-$ mouse brain. No product is amplified by any of the four pairs of primers in the absence of reverse transcriptase ($-/-$ -RT; lane 4), confirming that all products were amplified from cDNA rather than contaminating genomic DNA. Hypoxanthine phosphoribosyltransferase (HPRT) primers amplify a comparable level of product in all samples, indicating that the same amount of template is present. Amplified products by GIRK1, GIRK4, IRK1, and HPRT primers are of expected sizes.

of GIRK2, there is a concurrent loss of GIRK1 subunits that normally form heteromultimers with GIRK2.

Differences Between the GIRK2 Null Phenotypes and the Weaver Phenotypes. The GIRK2 $-/-$ and wv/wv mice showed striking differences. Visual inspection and histological examination of the brain and other organs of GIRK2 $-/-$ animals revealed no anomalies. GIRK2 $-/-$ mice exhibited normal cerebellar morphology except for the reduced GIRK1 and GIRK2 protein expression (Fig. 3B and D). Midbrain dopaminergic neurons and their dendrites also appeared normal despite the absence of GIRK2 protein (Fig. 3C). While male wv/wv mice are infertile, male GIRK2 $-/-$ mice are fertile; superovulated CD-1 mice mated with either GIRK2 $-/-$ males or their wild-type littermates produced a comparable number of fertilized eggs. The apparent normal phenotype in GIRK2 $-/-$ mice provides strong evidence that loss of homomeric GIRK2 channel and/or heteromeric GIRK1/GIRK2 channel function is not the primary cause of the weaver phenotype.

The Weaver Gene Dosage Effect. When GIRK2 $-/-$ mice were compared with mice carrying one or two copies of the wv allele (GIRK2 $wv/-$ and/or wv/wv), we found that both $-/-$ and $wv/-$ mice exhibit normal locomotive behavior, unlike the wv/wv mice. In $+/+$, $-/-$, and $wv/-$ animals, there was no obvious loss of TH-positive neurons or dendrites in the substantia nigra pars compacta or in the ventral tegmental area, whereas substantial cell loss was evident in the substantia nigra pars compacta of the wv/wv midbrain (Fig. 3C). In the substantia nigra pars compacta and ventral tegmental area of $wv/-$ mice, GIRK2 immunoreactivity was present but of lower intensity. In contrast to the heterozygous GIRK2 $+/-$ mice, most of the GIRK2 immunoreactivity in the $wv/-$ mice was found in the cell bodies of the dopaminergic neurons; the GIRK2 immunoreactivity in the dendrites was much reduced (Fig. 3C). The size and gross morphology of the cerebellum of $wv/-$ animals are not significantly different from that of the wild-type animals. Histologically, the $wv/-$ cerebellum appeared more similar to that of the $wv/+$ (8, 9) than the cerebellum of $+/+$ or wv/wv mice. The $wv/-$ granule cell layer often appeared thinner. The Purkinje cell layer was disorganized in various locations, and some of the Purkinje cells were found deep in the granule cell layer (Fig. 3D). The similarity between $wv/-$ and $wv/+$ cerebella and the difference between $wv/-$ and wv/wv cerebella suggest that cerebellar development is sensitive to the dosage of the GIRK2 G156S mutant gene.

Seizure Activities of GIRK2 Null Mice. The GIRK2 $-/-$ mice exhibited sporadic seizures characterized by jerking of

head and body, vocalization, and infrequently progression to a tonic-clonic seizure. Typically, the episodes lasted for 30 sec and were followed by complete physical inactivity. All witnessed seizures occurred when some kind of stress was exerted on the animal (changing cages, setting up matings), and the behavior of mice returned to normal after the seizure. Seizures were never observed before weaning and seemed to occur at equal frequencies in young and old mutant mice. Pharmacological challenge with the convulsant agent PTZ (29), a γ -aminobutyric acid antagonist, revealed that GIRK2 $-/-$ mice were hyperexcitable when challenged with a single injection of PTZ (50 mg/kg). At this dose, 70% of GIRK2 $-/-$ mice but only 25% of heterozygous or wild-type littermates developed severe stage 3 tonic-clonic seizures frequently associated with death ($P < 0.004$, Mann-Wilcoxon rank sum test). The severity of seizure, in the range from 0 to 3, was shifted toward increased severity in GIRK2 $-/-$ mice as compared with $+/-$ and $+/+$ controls. No statistically significant difference was seen between heterozygous and wild-type mice (Fig. 4A). The time taken to develop seizure activities was significantly shorter in GIRK2 $-/-$ mice compared with $+/-$ and $+/+$ animals ($P < 0.002$, unpaired t -test; Fig. 4B). Seizure activity has previously been noted in weaver mice and might be due to altered or reduced G protein-activated K^+ channel function (14). Our observation that GIRK1/GIRK2-deficient mice are susceptible to spontaneous and pharmacologically induced seizures was consistent with numerous studies demonstrating that agonists of G protein-coupled receptors, such as receptors for opioid peptides, somatostatin, and dopamine, can have significant effects on seizure thresholds in several different experimental seizure model systems (30).

In conclusion, we show that GIRK2-deficient mice have greatly reduced GIRK1 protein levels in the brain, suggesting that the majority of GIRK1 proteins in the brain associate with GIRK2. Phenotypic characteristics of GIRK2 $-/-$, $wv/-$, $wv/+$, and wv/wv mice suggest that gain-of-function and gene dosage mechanisms are responsible for the developmental defects in weaver mutants. Moreover, loss of GIRK2 function results in sporadic seizures and increased susceptibility to a convulsant agent, implicating GIRK1 and GIRK2 in the control of neural excitability *in vivo*.

We thank Paul Slesinger for his suggestions and discussions throughout the course of this work. We also thank Jan L. Breslow, James E. Darnell, Jr., Paolo Mocarelli, Annemarie Walsh, and the Rockefeller transgenic facility for their support. The research was supported by the




FIG. 3. (A) Coronal sections of brain from *GIRK2* $+/+$ and $-/-$ mouse brains stained with antibodies against the N terminus of *GIRK2*, the N terminus of *GIRK1*, and the C terminus of *IRK1* show that there is no detectable *GIRK2* and dramatically reduced *GIRK1* immunoreactivity in the *GIRK2* $-/-$ mice. The *IRK1* staining patterns are the same for these mice. CTX, cerebral cortex; HP, hippocampus; Th, thalamus. (Bar = 10 mm.) (B) Sagittal views of cerebella from *GIRK2* $+/+$ and $-/-$ mice stained with the antibodies described in A. Although there is no detectable *GIRK2* protein in the $-/-$ mice, there is still significant *GIRK1* staining, whereas the level of *IRK1* expression appears to be the same. g, granule cell layer; m, molecular layer. (Bar = 20 mm.) (C) Coronal sections of ventral midbrain from $+/+$, $-/-$, *wv/-*, and *wv/wv* mice are stained with antibodies against TH and the N terminus of *GIRK2*. The TH staining of $+/+$, $-/-$, and *wv/-* midbrain appears similar, whereas there are fewer TH-positive neurons in the substantia nigra pars compacta (SNc) of the *wv/wv* midbrain. *GIRK2* immunoreactivity is absent in the $-/-$ midbrain but can still be found in the *wv/-* and *wv/wv* mice, although the dendritic staining is dramatically reduced. SNr, substantia nigra pars reticulata;




FIG. 4. Susceptibility of GIRK2-deficient mice to PTZ-induced seizures. (A) Response of mice receiving one injection of 50 mg/kg PTZ i.p. (0, no response; 1, isolated twitches; 2, tonic-clonic convulsions; 3, tonic extension and/or death). GIRK2 $-/-$ mice ($n = 16$) tend to progress to more severe stages than $+/+$ or $+/-$ mice ($n = 13$ and 12 , respectively; $P < 0.004$, Mann-Whitney U-Wilcoxon rank sum test). No statistically significant difference was observed between $+/+$ and $+/-$ animals. (B) Seizure latency. The PTZ seizure latency was defined as the time elapsed from PTZ injection to the first obvious sign of tonic-clonic convulsion or tonic extension. The latency to seizures was shorter for the $-/-$ mice (*, $P < 0.002$, unpaired test).

National Parkinson Foundation (M.S.), a National Institute of Mental Health grant to the Silvio Conte Neuroscience Center at the University of California at San Francisco, and the University of California at San Francisco Neuroscience Graduate Program. L.Y.J. is a Howard Hughes Medical Institute investigator.

1. Sakman, B., Noma, A. & Trautwein, W. (1983) *Nature (London)* 303, 250–253.

2. Breitwieser, G.E. & Szabo, G. (1985) *Nature (London)* 317, 538–540.
3. Pfaffinger, P. J., Martin, J. M., Hunter, D. D., Nathanson, N. H. & Hille, B. (1985) *Nature (London)* 217, 536–538.
4. Hille, B. (1992) *Ion Channels of Excitable Membranes* (Sinauer, Sunderland, MA), 2nd Ed.
5. Jan, L. Y. & Jan, Y. N. (1994) *Nature (London)* 371, 119–122.
6. Kubo, Y. (1994) *Neurosci. Res. (N.Y.)* 21, 109–117.
7. Wickman, K. & Clapham, D. E. (1995) *Physiol. Rev.* 75, 865–885.
8. Rakic, P. & Sidman, R. L. (1973) *J. Comp. Neurol.* 152, 103–132.
9. Rakic, P. & Sidman, R. L. (1973) *J. Comp. Neurol.* 152, 133–162.
10. Hatten, M. E., Liem, R. K. & Mason, C. A. (1984) *J. Neurosci.* 4, 1163–1172.
11. Schmidt, M. J., Sawyer, B. D., Perry, K. W., Fuller, R. W., Foreman, M. M. & Ghatti, B. (1982) *J. Neurosci.* 2, 376–380.
12. Roffler-Tarlov, S. & Graybiel, A. M. (1984) *Nature (London)* 307, 62–66.
13. Harrison, S. M. W. & Roffler-Tarlov, S. (1994) *Dev. Dyn.* 200, 26–38.
14. Eisenberg, B. & Messer, A. (1989) *Neurosci. Lett.* 96, 168–172.
15. Patil, N., Cox, D. R., Bhay, D., Faham, M., Myers, R. M. & Peterson, A. S. (1996) *Nat. Genet.* 11, 126–129.
16. Slesinger, P. A., Patil, N., Liao, Y. J., Jan, Y. N., Jan, L. Y. & Cox, D. R. (1996) *Neuron* 16, 321–331.
17. Kofuji, P., Hofer, M., Millen, K. J., Millonig, J. H., Davidson, N., Lester, H. A. & Hatten, M. E. (1996) *Neuron* 16, 941–952.
18. Navarro, B., Kennedy, M. E., Velimirovic, B., Bhat, B., Peterson, A. S. & Clapham, D. E. (1996) *Science* 272, 1950–1953.
19. Surmeier, D. J., Mermelstein, P. G. & Goldowitz, D. (1996) *Proc. Natl. Acad. Sci. USA* 93, 11191–11195.
20. Tsaur, M.-E., Menzel, S., Lai, F. P., Espinosa, R., III, Concannon, P., Spielman, R. S., Hanis, C. L., Cox, N. J., Le Beau, M. M., German, M. S., Jan, L. Y., Bell, G. I. & Stoffel, M. (1995) *Diabetes* 44, 592–595.
21. Tybulewicz, V. L. J., Crawford, C. E., Jackson, P. K., Bronson, R. T. & Mulligan, R. C. (1991) *Cell* 65, 1153–1163.
22. Robertson, E. J. (1987) in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, ed. Robertson, E. J. (IRL Press, Oxford), pp. 71–112.
23. Sheng, M., Tsaur, M.-L., Jan, Y. N. & Jan, L. Y. (1992) *Neuron* 9, 271–284.
24. Liao, Y. J., Jan, Y. N. & Jan, L. Y. (1996) *J. Neurosci.*, in press.
25. Kobayashi, T., Ikeda, K., Ichikawa, T., Abe, S., Togashi, S. & Kumanishi, T. (1995) *Biochem. Biophys. Res. Commun.* 208, 1166–1173.
26. Duprat, F., Lesage, K., Guillemare, E., Fink, M., Hugnot, J. P., Bigay, J., Lazdunski, M., Romey, G. & Barhanin, J. (1995) *Biochem. Biophys. Res. Commun.* 212, 657–663.
27. Kofuji, P., Davidson, N. & Lester, H. A. (1995) *Proc. Natl. Acad. Sci. USA* 92, 6542–6546.
28. Lesage, F., Guillemare, E., Fink, M., Duprat, F., Heurteaux, C., Fosset, M., Romey, G., Barhanin, J. & Lazdunski, M. (1995) *J. Biol. Chem.* 270, 28660–28667.
29. Orloff, M. J., Williams, H. L. & Pfeiffer, C. C. (1949) *Proc. Soc. Exp. Biol. Med.* 70, 254–325.
30. Schwartzkroin, P. A. (1993) *Epilepsy: Models, Mechanisms and Concepts* (Cambridge Univ. Press, Cambridge, U.K.), 1st Ed.

VTA, ventral tegmental area. (Bar = 1 mm.) (D) High magnification views of parasagittal cerebellar sections from $+/+$, $-/-$, $wv/-$, and wv/wv mice. The sections are counterstained with toluidine blue or stained with antibody against the C terminus of IRK1, which stains the cell body and dendrites of the Purkinje cells as well as the dendrites in the granule cell layer. The $wv/-$ cerebellum is mostly wild-type in appearance except for regions with a Purkinje cell layer more disorganized and broader than that in GIRK2 $+/+$ and $-/-$ mice. Some Purkinje cells and their dendrites can be found in the granule cell layer of $wv/-$ mice. In the wv/wv cerebellum, there is no granule cell layer, and the Purkinje cells with disorganized dendrites are scattered throughout the cerebellum. m, molecular layer; p, Purkinje cell layer; g, granule cell layer; p/g, cell layer where both Purkinje cells and granule cells are found; m/p, cell layer where molecular layer and Purkinje cell layers collapse into one in the absence of granule cell layer; wm, white matter. (Bar = 0.2 mm.)

Perspectives Series: Molecular Medicine in Genetically Engineered Animals

Transgenesis in the Rat and Larger Mammals

Linda J. Mullins and John J. Mullins

Centre for Genome Research, The University of Edinburgh, Edinburgh EH9 3JQ, United Kingdom

Advances in biotechnology over the last ten years have made it possible for the researcher to alter gene expression *in vivo* in many diverse ways (1). With the establishment of embryonic stem (ES)¹ cell technology (2), more subtle and precise alterations can now be achieved than were previously possible using microinjection techniques. However, to date germline transmission has only been achieved with mouse ES cells, and microinjection continues to be the method most widely used for other species. While the mouse has a number of advantages, not least the depth of our knowledge of its genetics, other species are being increasingly used for transgenic studies due to their greater suitability for addressing specific questions. We will briefly review the application of transgenic technology to nonmurine species as it stands at present, with particular emphasis on developments appertaining to biomedical research.

Transgenesis by pronuclear injection

A number of significant limitations regarding the application of pronuclear injection to nonmurine animals have been identified (3), not least being the time and cost. Such limitations are due to longer gestation and generation times, reduced litter sizes, and higher maintenance costs. Further consideration must be given to the large numbers of fertilized eggs (and hence donor animals) required for microinjection, the high cost of carrying nontransgenic offspring to term, and the relatively low efficiency of gene integration. Such limitations are particularly severe for the production of bovine transgenics and, as a consequence, more significant departures from the standard procedures used for the mouse have been adopted for this species (4). For example, the use of *in vitro* embryo production in combination with gene transfer technology has played a large role in the development of transgenic cattle. The development of microinjected embryos through to the

morula/blastocyst stage in recipient rabbits or sheep, enables sexing, transgene screening, and cloning to take place before reintroduction into the natural host, providing that such screening methods are robust and reliable.

The major problem regarding pronuclear microinjection is that the exogenous DNA integrates randomly into chromosomal DNA. Position effects, where the transgene is influenced by its site of integration in the host chromosome (5), can have major consequences on the expression of the transgene, including loss of cell specificity, inappropriately high copy number-independent expression and complete silencing of the transgene. This is of greater concern in nonmurine transgenesis where the investment is higher. Position-independent, copy number-related expression can be achieved using sequences such as the locus control regions identified upstream of the β -globin gene cluster and downstream of the CD2 gene (6, 7), the A elements which flank the chicken lysozyme gene (8), and matrix attachment regions (9). Such elements have been shown to function across species barriers, and their incorporation into gene constructs can overcome position effects and improve expression of heterologous genes within specific cell types (5). In many cases, simply including large amounts of flanking sequences may be sufficient to overcome position effects and direct expression to specific tissues. To this end, the development and use of P1 (10), bacterial artificial chromosome (BAC) (11) and yeast artificial chromosome (YAC) vectors (12) for cloning of large segments of DNA, should greatly improve the chances of including important regulatory elements, including those involved in chromatin structure, within the transgene construct.

Embryonic stem cell technology

With the development of ES cell technology in the mouse (2), genetic manipulations can be performed in cell culture using appropriate selection strategies to permit the directed integration of the transgene to a specific region of the chromosome via homologous recombination. With the advent of homologous recombination, the researcher is able to insertionally inactivate, replace, or introduce subtle alterations to the endogenous gene of interest. Once the intended genetic change has been verified, the appropriate ES cells are introduced into blastocysts by microinjection, and, during subsequent gestation, may contribute to the developing embryo. If such a contribution is made, then by definition the resulting animal would be chimeric, being derived in part from the ES cells originating in culture. Assuming that the chimerism extends to the germline, then an appropriate breeding strategy will lead to the recovery of nonchimeric heterozygotes and, if viable, mice which are homozygous for the genetic change.

Most attempts to isolate and culture inner cell mass (ICM) cells from other species are based on the methods used for the

Address correspondence to John J. Mullins, Centre for Genome Research, The University of Edinburgh, King's Buildings, West Mains Road, Edinburgh EH9 3JQ, United Kingdom. Phone: 44-131-650-6846; FAX: 44-131-667-0164.

Received for publication 29 January 1996 and accepted 5 February 1996.

1. *Abbreviations used in this paper:* DAF, decay accelerating factor; ES, embryonic stem; HAR, hyperacute rejection; ICM, inner cell mass.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/96/12/0537/04 \$2.00

Volume 98, Number 11, Supplement 1996, S37-S40

mouse. ES cells are maintained in culture in the presence of mouse-derived differentiation-inhibiting agents, provided either as a media supplement or through cocultivation in the presence of feeder cells. It has been suggested that these mouse-derived agents do not adequately prevent differentiation of stem cells in species other than the mouse, and pluripotent rat ES cells, capable of producing chimeras, were found to grow best on primary rat embryonic fibroblasts as the feeder layer (13). Freshly isolated cells from ICMs have been injected into blastocysts to produce chimeric offspring in both sheep and cattle (14), and their totipotency at this stage is further demonstrated by their ability to produce offspring after transfer into enucleated oocytes (15). Such nuclear transfer techniques are potentially very useful for the production of clonal offspring and would avoid the initial chimeric generation necessitated by the injection of ES cells into blastocysts. Recently, bovine-specific culture methods have shown promise with cells of up to 27 d of age maintaining their ability to direct normal calf development following nuclear transfer (16). However, at the present time the reliable generation of bovine ES cell lines requires the pooling of ICMs from several blastocysts and further efforts are required to enable the long-term culture of clonal bovine ES cells. Although to date chimeric animals have been generated from several species including the pig (17), in no species other than the mouse has germline transmission of an ES cell been successfully demonstrated. This remains a major goal for the future and may well require the use of novel strategies which depart widely from the traditional methods used in the mouse.

Nonmurine species in biomedical research

Selected physiological questions may be more conveniently modelled in the rat or in larger species. Not only can physical size be an advantage for biochemical sampling and physiological analyses, but certain genes may provide useful information when introduced into, for example, the rat genome when parallel experiments in the mouse would be ineffective. Examples include the modulation of blood pressure by the mouse *Ren-2* gene (18) and the modeling of inflammatory disease (19). In both cases, but for different reasons, no phenotype was observed in the respective transgenic mice, highlighting one of the advantages of having alternative species for understanding physiological mechanisms and the etiology of disease. More recently, a number of transgenic experiments have been undertaken to investigate lipoprotein metabolism. The human apolipoprotein A-1 gene was successfully expressed in the rat (20), resulting in increased serum HDL cholesterol concentrations, and attempts to therapeutically lower apo B100, and hence LDL and lipoprotein(a) concentrations, in the rabbit were successful (21) but resulted in complications. Although the targeted expression of the apo B-editing protein in the liver of the transgenic rabbits resulted in reduced LDL and lipoprotein(a) concentrations as intended, many of the animals developed liver dysplasia, suggesting that high level expression of the editing protein had unforeseen and detrimental side effects, possibly via the editing of other important mRNAs. The rabbit has also been used in HIV-1 research, with the development of a line expressing the human CD4 protein on T lymphocytes (22). Susceptibility to HIV infection was demonstrated, and although the rabbits are less sensitive to infection than humans, they may represent an inexpensive alternative to primates for many studies.

Gene transfer in farm animals was initially aimed towards improving production efficiency, carcass quality (23), and disease resistance of livestock. However, it has been suggested that the simple over-expression of hormones such as growth hormone may have unacceptable side effects. Recently some elegant studies of growth using transgenic rats have been performed and are likely to yield valuable information on the biochemistry and physiology of growth (24, 25). A more successful application of transgenesis in farm animals has been the production of biomedically important proteins. The two most popular methods have been to direct expression to hematopoietic cells or to the lactating mammary gland. In the former case, transgenic swine expressing high levels of human hemoglobin were generated using the locus control region from the β -globin gene cluster to overcome positional effects and direct expression to the hematopoietic cells (26). However, due to its natural ability to synthesize and secrete large amounts of protein, the mammary gland has become the primary focus for the expression of heterologous proteins in large mammals. Transgene expression has been successfully directed to the mammary gland using promoter sequences from milk protein genes such as those encoding ovine β -lactoglobulin (BLG), goat β -casein, and murine whey acidic protein. The BLG promoter was used to direct expression of human α_1 -antitrypsin in lines of transgenic mice and sheep (27). Interestingly, a wide variation in expression was observed between mouse lines, and from one lactation to another within a single line. In sheep however, similar high levels of heterologous protein were expressed in milk over consecutive lactations and over several generations in a given transgenic line, allowing the viable development of a flock of transgenic sheep. In separate studies high levels of expression of human tissue plasminogen activator were obtained in goat's milk under the control of the goat β -casein promoter (28). The development of suitable purification methods and the use of transgenically produced proteins in clinical trials are well advanced, and, if successful, will have important implications for the production of human proteins in transgenic livestock. Poor expression of the ovine promoter in the mouse may reflect species differences in recognizing heterologous versus homologous promoters and raises questions concerning the predictive value of mouse models. At best therefore the generation of transgenic mice may, in certain cases, only be a guide to the potential success of a transgene construct in another species.

Gene transfer could equally be used to enhance the quality and suitability of milk derived from domesticated animals as a food for human consumption. Human milk is devoid of β -lactoglobulin, which is responsible for most of the allergies to cows' milk, and has a relatively high content of lactoferrin, which is important in iron transport and combating bacterial infections. One could envisage in the future the reduction of saturated fat content in cows' milk and the knock-out of unwanted proteins or their replacement with other more useful components. Through the manipulation of milk constituents it should be possible to more closely emulate the desirable components of human milk. The alteration of milk composition would appear to be a practical possibility given that milk micelles are remarkably tolerant to changes in composition, as demonstrated by the knock-out of the mouse β -casein gene (29). Ethical concerns regarding the generation of transgenic animals, which have been engineered specifically for pharmaceutical, medical, or nutritional reasons, lie outside the scope

of this overview, however it must be clearly ascertained that expression of a transgene does not compromise the animal.

Xenograft organs for transplantation surgery

The shortage of human organs for transplantation has raised interest in the possibility of xenotransplantation, i.e. the use of animal organs (30). However, the major barrier to successful xenogeneic organ transplantation is the phenomenon of complement-mediated hyperacute rejection (HAR), brought about by high levels of circulating natural antibodies that recognize carbohydrate determinants on the surface of xenogeneic cells. After transplantation of the donor organ, a massive inflammatory response ensues through activation of the classical complement cascade. This leads to activation and destruction of the vascular endothelial cells and, ultimately, the donor organ. The membrane-associated complement inhibitors, endogenous to the donor organ, are species restricted and thus confer only limited resistance. The complement cascade is regulated at specific points by proteins such as decay accelerating factor (DAF), membrane cofactor protein, and CD59. These regulators of complement activation are species specific. The initial strategy used to address HAR in porcine-to-primate xenotransplantation was to produce transgenic pigs expressing high levels of the human terminal complement inhibitor, hCD59. This was shown to protect the xenogeneic cells from human complement-mediated lysis *in vitro* (31). More recently, organ transplantation has been achieved using donor pigs which expressed human DAF on their endothelium (32), or both DAF and CD59 on erythrocytes, such that the proteins translocated to the cell membranes of endothelial cells (33). After transplantation, the pig hearts survived in recipient baboons for prolonged periods without rejection (33). Clearly, such genetic manipulations are bringing xenotransplantation ever closer to reality. If the isolation of suitable ES cells and application of homologous recombination becomes a reality in the pig, it may be possible to knockout the antigenic determinants to which antispecies antibodies bind, as a further strategy for eliminating HAR.

Summary

The use of nonmurine species for transgenesis will continue to reflect the suitability of a particular species for the specific questions being addressed, bearing in mind that a given construct may react very differently from one species to another. The application of transgenesis in the pig should produce major advances in the fields of transfusion and transplantation technology, while alterations in the composition of milk in a range of domesticated animals will have major effects on the production of pharmacologically important proteins and could eventually lead to the development of human milk substitutes. Despite the lack of germline transmission to date, major efforts continue to be directed towards the generation and use of ES cells from nonmurine species, using both traditional and new technologies, and the availability of such cells is likely to accelerate both the use of such species and the precision with which genetic changes can be introduced.

References

1. Murphy, D., and D.A. Carter, editors. 1993. Transgenesis techniques: principals and protocols. *In* Methods in Molecular Biology. Vol. 18. Humana Press Inc., Totowa, NJ.
2. Hooper, M.L. 1992. Embryonal Stem Cells, Introducing Planned Changes into the Animal Germline. Harwood Academic Publishers, Berks, UK.
3. Mullins, J.J., and L.J. Mullins. 1993. Transgenesis in non-murine species. *Hypertension (Dallas)*. 22:630-633.
4. Eystone, W.H. 1994. Challenges and progress in the production of transgenic cattle. *Reprod. Fertil. Dev.* 6:647-652.
5. Clark, A.J., P. Bissinger, D.W. Bullock, S. Damak, R. Wallace, C.B.A. Whitelaw, and F. Yull. 1994. Chromosomal position effects and the modulation of transgene expression. *Reprod. Fertil. Dev.* 6:589-598.
6. Orkin, S.H. 1990. Globin gene regulation and switching. *Cell*. 63:665-672.
7. Lake, R.A., D. Wotton, and M.J. Owen. 1990. A 3' transcriptional enhancer regulates tissue-specific expression of the human CD2 gene. *EMBO (Eur. Mol. Biol. Organ.) J.* 9:3129-3136.
8. Bonifer, C., M. Vidal, F. Grosveld, and A.E. Sippel. 1990. Tissue specific and position independent expression of the complete gene for chicken lysozyme in transgenic mice. *EMBO (Eur. Mol. Biol. Organ.) J.* 9:2843-2848.
9. McKnight, R.A., A. Shamay, L. Sankaran, R.J. Wall, and L. Hennighausen. 1992. Matrix-attachment regions can impart position-independent regulation of a tissue-specific gene in transgenic mice. *Proc. Natl. Acad. Sci. USA*. 89:6943-6947.
10. Pierce, J.C., B. Sauer, and N. Sternberg. 1992. A positive selection vector for cloning high molecular weight DNA by the bacteriophage P1 system: improved cloning efficacy. *Proc. Natl. Acad. Sci. USA*. 89:2056-2060.
11. Shizuya, H., B. Birren, U.-J. Kim, V. Mancino, T. Slepak, Y. Tachiiri, and M. Simon. 1992. Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in *Escherichia coli* using an F-factor-based vector. *Proc. Natl. Acad. Sci. USA*. 89:8794-8797.
12. Larin, Z., A.P. Monaco, and H. Lehrach. 1991. Yeast artificial chromosome libraries containing large inserts of mouse and human DNA. *Proc. Natl. Acad. Sci. USA*. 88:4123-4127.
13. Iannaccone, P.M., G.U. Taborn, R.L. Garton, M.D. Caplice, and D.R. Brenin. 1994. Pluripotent embryonic stem cells from the rat are capable of producing chimeras. *Dev. Biol.* 163:288-292.
14. Anderson, G.B. 1992. Isolation and use of embryonic stem cells from livestock species. *Anim. Biotechnol.* 3:165-175.
15. Sims, M., and N.L. First. 1993. Production of calves by transfer of nuclei from cultured inner cell mass cells. *Proc. Natl. Acad. Sci. USA*. 90:6143-6147.
16. First, N.L., M.M. Sims, S.P. Park, and M.J. Kent-First. 1994. Systems for production of calves from cultured bovine embryonic cells. *Reprod. Fertil. Dev.* 6:553-562.
17. Wheeler, M.B. 1994. Development and validation of swine embryonic stem cells: a review. *Reprod. Fertil. Dev.* 6:563-568.
18. Mullins, J.J., J. Peters, and D. Ganten. 1990. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. *Nature (Lond.)*. 344:541-544.
19. Hammer, R.E., S.D. Maika, J.A. Richardson, J.-P. Tang, and J.D. Tauger. 1990. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β_2 -m: an animal model of HLA-B27-associated human disorders. *Cell*. 63:1099-1112.
20. Swanson, M.E., T.E. Hughes, I. St. Denny, D.S. France, J.R. Paterniti, C. Tapparelli, P. Gfeller, and K. Burki. 1992. High level expression of human apolipoprotein A-I in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-I. *Transgenic Res.* 1:142-147.
21. Yamanaka, S., M.E. Balestra, L.D. Ferrell, J. Fan, K.S. Arnold, S. Taylor, J. M. Taylor, and T.L. Innerarity. 1995. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. *Proc. Natl. Acad. Sci. USA*. 92:8483-8487.
22. Dunn, C.S., M. Mehtali, L.M. Houdebine, J.-P. Gut, A. Kim, and A.-M. Aubertin. 1995. Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits. *J. Gen. Virol.* 76:1327-1336.
23. Solomon, M.B., V.G. Pursel, E.W. Paroczay, and D.J. Bolt. 1994. Lipid composition of carcass tissue from transgenic pigs expressing a bovine growth hormone gene. *J. Anim. Sci.* 72:1242-1246.
24. Flavell, D.M., T. Wells, S.E. Wells, D.F. Carmignac, G.B. Thomas and I.C. A. F. Robinson. A new dwarf rat I: Dominant negative phenotype in GRF-GH transgenic growth retarded (Tgr) rats. 1995. Abstracts of the 77th Annual meeting of The Endocrine Society. P2-239.
25. Wells, T., D.M. Flavell, S.E. Wells, D.F. Carmignac, G.B. Thomas and I.C. A.F. Robinson. A new dwarf rat II: GH secretion, responses to GRF and somatostatin, and growth stimulation by GRF in the GRF-GH transgenic (Tgr) rat. 1995. Abstracts of the 77th Annual meeting of The Endocrine Society. P2-240.
26. Sharma, A., M.J. Martin, J.F. Okabe, R.A. Truglio, N.K. Dhanjal, J.S. Logan, and R. Kumar. 1994. An isologous porcine promoter permits high-level expression of human hemoglobin in transgenic swine. *Biotechnology*. 12:55-59.
27. Carver, A.S., M.A. Dalrymple, G. Wright, D.S. Cottom, D.B. Reeves, Y.H. Gibson, J.L. Keenan, J.D. Barras, A.R. Scott, A. Colman, and I. Garner. 1993. Transgenic livestock as bioreactors: stable expression of human alpha-1-antitrypsin by a flock of sheep. *Biotechnology*. 11:1263-1270.
28. Ebert, K.M., J.P. Selgrath, P. DiTullio, J. Denman, T.E. Smith, M.A. Memon, J.E. Schindler, G.M. Monastersky, J.A. Vitale, and K. Gordon. 1991. Transgenic production of a variant of human tissue-type plasminogen activator in goat milk: generation of transgenic goats and analysis of expression. *Biotechnology*. 9:835-838.

29. Kumar, S., A.R. Clarke, M.L. Hooper, D.S. Home, A.J.R. Law, J. Leaver, A. Springbett, E. Stevenson, and J.P. Simons. 1994. Milk-composition and lactation of beta-casein-deficient mice. *Proc. Natl. Acad. Sci. USA*. 91: 6138-6142.

30. Dorling, A., and R.I. Lechler. 1994. Prospects for xenografting. *Curr. Opin. Immunol.* 6:765-769.

31. Fodor, W.L., B.L. Williams, L.A. Matis, J.A. Madri, S.A. Rollins, J.W. Knight, W. Velander, and S.P. Squinto. 1994. Expression of a functional human-complement inhibitor in a transgenic pig as a model for the prevention of xeno-

neic hyperacute organ rejection. *Proc. Natl. Acad. Sci. USA*. 91:11153-11157.

32. Rosengard, A.M., N.R.B. Cary, G.A. Langford, A.W. Tucker, J. Wallwork, and D.J.G. White. 1995. Tissue expression of human-complement inhibitor, decay-accelerating factor, in transgenic pigs: a potential approach for preventing xenograft rejection. *Transplantation (Baltimore)*. 59:1325-1333.

33. McCurry, K.R., D.L. Kooyman, C.G. Alvarado, A.H. Cotterell, M.J. Martin, J.S. Logan, and J.L. Platt. 1995. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. *Nature Med.* 1:423-427.

ustomized proteins of high
nderstandably, their primary
ed lower manufacturing cost
At present, this fledgling
sgenic animals. If the
s that there are ample
ling new opportunities for the
natically it is not likely to see

imal cell and bacterial cell
r. Bio/Technology 1993;

Proc. Certification System
enza, Italy, March 23-26,

roducts for Human Use
ices, Public Health

etic polymorphism of k-
sing properties. Neth.

modification of milk
58(suppl):299S-306S.



TRANSGENIC LIVESTOCK: PROGRESS AND PROSPECTS FOR THE FUTURE



R.J. Wall

Gene Evaluation and Mapping Laboratory, Agricultural Research Service, USDA,
Beltsville, Maryland, 20705 USA

ABSTRACT

The notion of directly introducing new genes or otherwise directly manipulating the genotype of an animal is conceptually straightforward and appealing because of the speed and precision with which phenotypic changes could be made. Thus, it is of little wonder that the imagination of many an animal scientist has been captivated by the success others have achieved by introducing foreign genes into mice. The private sector has embraced transgenic livestock technology resulting in the formation of two new industries. However, before transgenic farm animals become a common component of the livestock production industry, a number of formidable hurdles must be overcome. In this brief communication, the technical challenges are enumerated and possible solutions are discussed.

Key words: transgenic livestock, gene transfer, microinjection

INTRODUCTION

The definition of transgenic animals is evolving. For the purpose of this paper a transgenic animal is one containing recombinant DNA molecules in its genome that were introduced by intentional human intervention. In this review I will focus on animals in which transgenes were introduced into preimplantation embryos by pronuclear microinjection, with the intended consequence of producing germline transgenics as opposed to somatic cell transgenics. Though there are other means of introducing genes into preimplantation embryos (20,29), pronuclear microinjection, basically as originally described by Jon Gordon (25), and as modified for livestock in our laboratory (85), is still the predominant method employed.

Acknowledgments

Many of the concepts, conclusions and visions of the future included in this manuscript have evolved over the years from discussions at our Friday afternoon lab meeting. Vern Pursel and Caird Rexroad, Jr., who pioneered transgenic livestock technology, provided the leadership. In recent years Ken Bondioli, David Kerr, Paul Hyman and Uli Tillmann have provided valuable new insights and new approaches that have and will advance the field.

WHY MAKE TRANSGENIC ANIMALS?

A Medline search reveals that over 6,000 scientific articles have been published in which transgenic animals (mostly mice) were used to answer basic research questions. By contrast 289 papers dealt with transgenic livestock, of which 24% were reviews. The limited publication record for transgenic livestock species reflects the high costs and technical difficulties associated with producing transgenic livestock more than lack of applicability of this technology to farm animals. A number of well defined goals have been enumerated in the numerous review articles written by animal scientists. Not surprisingly, many of the proposed applications closely parallel the long term objectives of animal agriculture.

In theory, transgenic technology provides a mechanism by which economically important traits can be attained more rapidly than by selective breeding without concern of propagating associated, possibly undesirable, genetic characteristics. If genetic precision and speed of improvement were the only advantages of transgenic technology, use of that methodology might be difficult to justify. That is because current cost of producing transgenic animals are high and understanding of the appropriate genetic manipulations required to influence economically important traits is limited. However, transgenic technology offers much more. Genes can be transferred across species boundaries and can be modified to function very differently than they do in their native form (gene products, tissue specificity, and timing of expression can be altered). The ability to redirect expression of genes to another organ has spawned the transgenic bioreactor industry. For the most part, transgenic bioreactors are farm animals designed to produce new proteins in their milk or other body fluids. It is envisioned that this approach will have application in both food production and the biomedical arena. Modifying the composition of milk through genetic engineering is the topic of Dr. Bremel's paper in these proceedings and will not be dealt with here.

TRANSGENIC LIVESTOCK PROJECTS

For the sake of brevity, only a very brief summary of the 37 gene constructs that have been tested in livestock will be reported here. The reader is referred to two excellent reviews that list those constructs and their consequences (16,53).

The Transgene.

The power of transgenic technology is derived from the introduction of genetic information with new functionality. The strategy for building a transgene (fusion gene) involves selecting a genetic regulatory element (often called promoters, but usually containing both an enhancer element and a promoter) that will determine the tissue in which the gene is to be expressed and the time and magnitude of expression. In some cases, the regulatory element can act as a switch, allowing the transgene to be turned on and off at will. The second part of the gene construct consists of DNA sequence encoding the desired protein (often referred to

as the structural component of a livestock experiment). A hormone in a control consisted of the regulatory coding sequence for an enzyme, and its gene circulating zinc or cadmium. The MT-GH fusion gene experiments GH expression could not be turned off. Being tested (23,26). activate or repress transcription in their current form. if they are not, they probably lead to improvement.

Applied Transgenic Projects

The vast majority of those publications on enhancement. Growth those publications on structural genes and regulatory elements frequently used, approximately terminal repeats (LT CMV, a DNA virus. promoters from phosphoenolpyruvate constructs were tested use of MT-GH fusion

Seven transgenic immunologically-related (5,13,41,67). Though the projects, none of the beneficial effect of the

Very recently production characteristics if no unforeseen adverse marketed livestock

Biomedical Transgenic

Other proposed agricultural in nature the feasibility of

articles have been
d to answer basic
livestock, of which
livestock species
with producing
chnology to farm
in the numerous
y of the proposed
culture.

ism by which
an by selective
esirable, genetic
were the only
it be difficult to
ds are high and
ed to influence
chnology offers
can be modified
products, tissue
ity to redirect
enic bioreactor
ds designed to
oned that this
medical arena.
ie topic of Dr.

ne constructs
is referred to
(16,53).

roduction of
a transgene
often called
omoter) that
he time and
as a switch,
of the gene
referred to

as the structural component of the transgene). For example, in the first transgenic livestock experiment (28) we wanted to increase the levels of circulating growth hormone in a controlled manner. The gene construct used to accomplish this consisted of the regulatory element of a metallothionein (MT) gene fused to the coding sequence for growth hormone (GH). Metallothionein is an inducible liver enzyme, and its gene is usually quiescent (turned off) until a threshold level of circulating zinc or cadmium triggers transcription. Therefore, it was expected that the MT-GH fusion gene would be silent until the animals were fed zinc. In those experiments GH expression could be induced but, in most cases, the transgene could not be turned off completely. New more complex inducible approaches are now being tested (23,26). These new systems rely on tetracycline or its analogs to activate or repress transgene expression. It is too early to know if these strategies, in their current form, will be more tightly regulated than the MT system. However, if they are not, the general paradigm on which the new systems are based will probably lead to improved inducible systems

Applied Transgenic Projects.

The vast majority of original research reports have focused on growth enhancement. Growth hormone (GH) was the structural gene employed in 13 of those publications and the gene for growth hormone releasing factor in four. Other structural genes tested include IGF-1, cSKI and an estrogen receptor. The regulatory elements derived from MT genes, from various species, were most frequently used, appearing in nine of the growth-related fusion genes. Long terminal repeats (LTR) from two retroviruses, MLV and RSV, and sequence from CMV, a DNA virus, served as regulatory components of transgenes, as have the promoters from albumin, prolactin, skeletal actin, transferrin and phosphoenolpyruvate carboxykinase (PEPCK) genes. All but two of 21 growth constructs were tested in pigs and the most striking phenotypes resulted from the use of MT-GH fusion genes (53).

Seven transgenes designed to enhance disease resistance and to produce immunologically-related molecules have been introduced into pigs and sheep (5,13,41,67). Though desirable expression patterns have been reported in several of the projects, none of the studies has progressed to the point of demonstrating a beneficial effect of transgene products.

Very recently it has been reported that transgenic sheep with enhanced wool production characteristics have been produced (9). The results are quite promising; if no unforeseen anomalies occur, transgenically produced wool maybe the first marketed livestock product.

Biomedical Transgenic Projects.

Other proposed transgenic farm animal applications are decidedly non-agricultural in nature. One of the first transgenic animal companies demonstrated the feasibility of producing new animal products by manufacturing human

hemoglobin in pigs, to serve as a principal component of a human blood substitute (59). Human antibodies have also been produced in transgenic mice (62). Another area where transgenic animals, especially pigs, will have a significant impact on society will be in the development of human genetic disease models. To date, genetic disease models have been generated in mice for atherosclerosis (6), sickle cell anemia (18), Alzheimer's disease (21), autoimmune diseases (44), lymphopoiesis (33), dermatitis (55), and prostate cancer (61). These models for the most part require "knocking out" the function of a gene or replacing an existing gene with a mutant form. Many of these models will have to be replicated in farm animals to be useful. Unfortunately, the stem cell technology required to generate most of the disease models is still in development for livestock (51).

Finally, a new use not reported in the above mentioned reviews deserves note. The objective of this new endeavor is to genetically engineer animals, primarily pigs, so that their organs can be used as xenografts for humans. Preliminary studies to test the concept have been performed in mice (40,42) and transgenic pigs have now been produced (19,54). Though several strategies are being explored, the general approach has been to block activation of complement, which is normally part of the acute transplantation rejection response. These organs are intended for temporary use, until an appropriate human organ becomes available. However, as the technology develops, a driving force will be the design of transgenic organs for extended use or permanent transplantation.

CHARACTERISTICS OF TRANSGENIC ANIMALS

Transgenic livestock projects are costly, primarily because the process is inefficient. Production costs range from \$25,000 for a single founder pig to over \$500,000 for a single functional founder calf (64). The calculation for cattle was based on obtaining zygotes by superovulation of embryo donors, the normal practice for all mammalian species. However, the costs are reduced by as much as a third if oocytes derived from ovaries collected at slaughter are the starting material. The remainder of this review will be devoted to characterizing the transgenic animal model, to identify points in the process that reduce efficiency, and finally discussing possible approaches that have been proposed to overcome major hurdles to progress.

Transgene Integration.

Even though several hundred copies of a transgene are microinjected, any transgene that becomes incorporated into the genome generally does so at a single location. Exceptions are rare (58). Thus, transgenic founder animals are hemizygous for transgenes. It is also common for a transgene locus to contain multiple copies of the transgenes arranged in a head-to-tail array. These two characteristics of transgene loci should provide clues to the mechanism by which transgenes integrate. So far, few researchers have formulated compelling hypotheses to explain the event (2,47) and the hypotheses that have been proposed remain untested.

Without knowledge of
to devise approaches to

Transgene integration
animals (cattle, sheep
and rats, Table 1).

Table 1. Examples of
several laboratories.

Species	Injected & transferred embryos (No.)	St
Mice	12,314	
Rabbits	1,907	
Rat	1,403	
Cattle ^c	1,018	
Pigs	19,397	
Sheep	5,424	

^a Number of experiments
tested.

^b The value for cattle includes

^c Eleven thousand two hundred
eighteen developed to maturity

Transgene Expression

Even after the creation of a transgenic animal, the transgene to be expressed is about half of transgenic offspring. It is not clear in only half the lines (ectopic expression), development. Our lack of it difficult to design transgene patterns (no expression in animals has been at near highly active genes. Other transgenic regions. The transgene

n blood substitute
nice (62). Another
ificant impact on
s. To date, genetic
is (6), sickle cell
4), lymphopoiesis
r the most part
ting gene with a
m animals to be
ate most of the

views deserves
ineer animals,
s for humans.
ice (40,42) and
strategies are
f complement,
sporadic. These
organ becomes
the design of

he process is
r pig to over
or cattle was
rmal practice
as a third if
material. The
genic animal
y discussing
to progress.

ected, any
at a single
hemizygous
le copies of
eristics of
transgenes
s to explain
1 untested.

Without knowledge of the molecular mechanism it is going to be extremely difficult to devise approaches to make transgene integration more efficient.

Transgene integration efficiency is low and ranges from about 1% in farm animals (cattle, sheep and pigs) to about 3% in laboratory animals (mice, rabbits and rats, Table 1).

Table 1. Examples of embryo survival and transgene integration efficiencies from several laboratories.

Species	Injected & transferred embryos (No.)	Studies ^a (No.)	Offspring ^b (No.)	Transgenic animals produced		
				Per Offspring (%)	Per embryo injected & transferred (%)	Refs.
Mice	12,314	18	1847	17.3	2.6	(63)
Rabbits	1,907	1	218	12.8	1.5	(28)
Rat	1,403	5	353	17.6	4.4	(45)
Cattle ^c	1,018	7	193	3.6	0.7	(30)
Pigs	19,397	20	1920	9.2	0.9	(53)
Sheep	5,424	10	556	8.3	0.9	(53)

^a Number of experiments, which in most cases was equivalent to number of different gene constructs tested

^b The value for cattle includes both fetuses and live born calves.

^c Eleven thousand two hundred and six eggs were microinjected and cultured. One thousand and eighteen developed to morula or blastocysts and were transferred into recipient cows.

Transgene Expression

Even after the one in 33 to one in 150 injected and transferred eggs results in a transgenic animal the efficiency of the process is further diminished by failure of the transgene to be transcribed. Transgenes are expressed (transcribed) in only about half of transgenic lines, though some specific transgenes are expressed in a higher proportions (15-27). If a founder expresses its transgene, so do its transgenic offspring. It is not clear why some transgenes are expressed in all lines and others in only half the lines. Transgenes are sometimes activated in unintended tissues (ectopic expression), and timing of expression can be shifted relative to development. Our lack of understanding of essential genetic control elements makes it difficult to design transgenes with predictable behavior. The aberrant expression patterns (no expression or wrong expression) seen in some lines of transgenic animals has been attributed to the so-called "position effect." If a transgene lands near highly active genes, the transgene's behavior maybe influenced by endogenous genes. Other transgenes may locate in transcriptionally inactive (heterochromatin) regions. The transgene may function normally or be completely silenced by the

heterochromatin. It is likely that both of these factors (position effect and unidentified control elements) contribute to lack of transgene expression in some lines and variable expression in other lines. Some of these problems will be obviated by use of "boundary" DNA sequences that block the influence of surrounding genes (34,43). Refining transgenic technology for farm animals will remain a challenging task in part because experimentation will often have to be conducted in the species of interest. That is because transgene expression and the physiological consequences of transgene products in livestock are not always accurately predicted in transgenic mouse studies (28,48).

Transgene transmission.

Because founder animals are usually single integrant hemizygous for the transgene, one would expect 50% of their offspring to inherit a copy of the transgene locus. This is true for about 70% of transgenic founder mice (49). The remaining founders either do not transmit transgenes to their offspring or transmit transgenes at a low frequency (52,53). It is commonly thought that the non-Mendelian inheritance is the result of transgene mosaicism in germ cells. This could be caused by late integration of transgenes during embryonic development (66). It has been proposed that non-Mendelian inheritance patterns can also be caused by diminished fertilizing ability of transgene bearing sperm (17). The latter explanation may be a special case, because the thymidine kinase gene used in that study was inadvertently expressed in testes.

POTENTIAL SOLUTIONS FOR IMPROVING EFFICIENCY

Testing Transgenes.

Because the "rules" for transgene design are still vague, it is important to have a reliable system for testing gene constructs. The most cost effective method of characterizing the performance of a transgene is cell culture transfection studies. Unfortunately, such studies have a low predictive value (50). The next most cost effective method for testing gene constructs is production of transgenic mice, which as mentioned above do not faithfully predict a transgene's performance in livestock species. Nevertheless, a reasonable amount of useful information about transgene function can be derived from transgenic mouse studies. Currently, the only approach that yields truly informative data is testing transgenes in the livestock species of interest. This is obviously an unsatisfactory, time consuming, expensive testing option. One alternative approach that we are exploring is based on the fact that transgenes will function after being "shot" into somatic tissue. We have been focusing our efforts on the mammary gland, but almost any target organ should be amenable to this approach. We have recently demonstrated that both RNA and protein can be detected following introduction of transgenes into sheep mammary tissue, *in situ* (22,37). Once we confirm that "gene-gunned" transgenes function as they do in transgenic animals, this approach should dramatically reduce the costs and time of evaluating gene constructs.

Improving Integrat
From Table
than for laborator
microinject than eg
reliably inflate pro
problem occurs afte
contribute to diffe
integration occurs
microinject before
the most part th
microinjections are
species (for a full
zygotes early have
personal commun
microinjection and

One way to
phase is to introd
sperm-mediated g
approach has gene
some promise (57)
can bind transgene
cases the gene per
transgene DNA be
Spadafora, person
approach has been
In that study, tr
fertilizing oocytes
transfect and sel
scheme could be u
transfecting testes

Retroviral-r
for introducing tr
technique solves
inefficiencies by g
Furthermore, ret
therefore the tech
which are relative
would not be a sig
pool, expressed i

Improving Integration Frequency

From Table 1 it is clear that integration rates are lower for livestock species than for laboratory animals. Eggs of livestock species are more difficult to microinject than eggs of laboratory animals. However, competent microinjectors can reliably inflate pronuclei with DNA-containing solutions. Furthermore, integration problem occurs after the transgene is deposited. But timing of microinjection may contribute to differences in integration efficiency. It is thought that transgene integration occurs during DNA replication (2), so it would be advantageous to microinject before or during early S-phase preceding the first mitotic division. For the most part that is when laboratory animal eggs are microinjected, but microinjections are apparently performed during late S-phase or later in livestock species (for a full discussion see (63)). Efforts to inject *in vitro* fertilized bovine zygotes early have failed because of difficulties in visualizing pronuclei (K. Bondioli, personal communication and unpublished data). Efforts to synchronize microinjection and S-phase in bovine zygotes have thus far not been fruitful (24).

One way to insure that the transgene is in place before the first mitotic S-phase is to introduce the transgene at fertilization. That could be achieved by sperm-mediated gene transfer (4,38). Notwithstanding the controversy this approach has generated (8), it clearly represents an intriguing method that shows some promise (57). Accumulating evidence suggests that sperm of several species can bind transgenes (11,32,39,68) and carry the genes into oocytes where in some cases the gene persists (4,12,31). However, it appears that in almost all cases, the transgene DNA becomes rearranged or otherwise mutated by the process (Corrado Spadafora, personal communication). Another potential sperm-based delivery approach has been foretold by a pioneering study conducted by Ralph Brinster (7). In that study, transplanted spermatogonial cells generated sperm capable of fertilizing oocytes and offspring were produced. If a means is found to culture, transfect and select spermatogonia with transgenes, Brinster's transplantation scheme could be used to produce transgenic animals. Others have proposed directly transfecting testes as a means of transforming sperm (56).

Retroviral-mediated gene transfer is also a potentially alternative approach for introducing transgenes into embryos with high efficiency (29,36). Though the technique solves the low integration frequency problem, it creates other inefficiencies by generating mosaic founders that may not transmit their transgene. Furthermore, retroviruses can carry only a limited amount of exogenous DNA and therefore the technique limits the size of transgenes. If cDNA based transgenes, which are relatively short, were efficiently expressed, the transgene size restriction would not be a significant problem. However, many cDNA based gene constructs are poorly expressed in transgenic animals (66).

Selection of transgenic embryos.

With no obvious or immediate solution for improving integration frequency, what else can be done to increase efficiency of producing transgenic livestock? One of the most widely discussed approaches is selection of transgenic embryos before they are transferred to recipients (1,14,35,46). If transgenic preimplantation embryos can be identified by analyzing embryo biopsies with the polymerase chain reaction (PCR), the number of recipients required could be greatly reduced. For example in Dr. Bondioli's study ((30), Table 1), 1,018 bovine embryos were transferred into over 1000 cows resulting in seven transgenic calves and fetuses. If embryo selection had been possible, fewer than 20 recipients would have been required. Unfortunately, mounting evidence suggests that this approach will not work. In two very similar studies (10,14) microinjected mouse embryos were cultured to the 8-cell stage, and blastomeres were isolated and analyzed for the transgene by PCR. In our study (10) none of the 8-cell embryos had transgenes in more than 4 blastomeres. We speculate that immediately upon microinjection, transgene copies join to form multi-copy circular arrays. One of these arrays may eventually become integrated, while the non-integrated arrays segregate as daughter blastomeres are formed. If integration occurs after the one-cell stage, some blastomeres may not contain an array, even though the embryo is transgenic. The converse is also possible (all blastomeres acquire arrays but none integrate). Analysis of embryo biopsies could therefore be misleading.

Another scheme for selecting transgenic embryos before transfer is based on expression of a selectable marker-containing transgene. The preliminary results from two recent studies (3,60) appear to be promising. In both studies, transgenes containing a neomycin resistance gene (neo) were microinjected into pronuclei of mice (60) or bovine (3) embryos. The embryos were then cultured in the presence of G418, a neomycin analog, in the hope of killing embryos that did not express the neo gene. Because this approach is based on gene expression and because transgenes can be expressed without being integrated, embryos containing unintegrated copies of the transgene could survive the selection process. However, since G418 interferes with protein synthesis, the blastomeres that expressed the neo gene would have a developmental advantage over those that did not. Therefore, the blastomeres expressing the neo gene might divide more rapidly and have a higher probability of participating in the formation of the inner cell mass (66). Further studies will have to be conducted to determine if this scheme has merit.

IN THE FUTURE

The tools for gene transfer are in hand, albeit the process is inefficient. Over the next decade, bioreactor and xenograft industries will mature and useful new products will be marketed. The value of possible products will drive the technology as funding for basic research from conventional sources becomes increasingly limited. Researchers will need to develop a better understanding of how mammalian genes are controlled, and identify key genes in regulatory pathways of

phenotypic characterization technology to animal technology. Progress in the field is potentially powerful. The efficiency of production in the horizon looks bright with the knowledge

1. Behboodi E, Andersson G. Bovine embryos with transgenes. *Theriogenology* 1993;76:3392-3399.
2. Bishop JO, Smith P. Transgenic animals. *Med* 1989;6:283-298.
3. Bondioli KR, Wall R. Transgenic animals. *Theriogenology* 1996;49:1-10.
4. Brackett BG, Boranowski A. Mammalian spermatogenesis. *Theriogenology* 1971;68:353-357.
5. Brem G. Inheritance of transgenes. *Reprod Devel* 1993;3:1-10.
6. Breslow JL. Transgenic animals. *Acad Sci USA* 1993;90:1-10.
7. Brinster RL, Avarbock M. Transgenic animals. *Theriogenology* 1991;44:1-10.
8. Brinster RL, Sandberg M. Transgenic mice. *Theriogenology* 1991;44:1-10.
9. Bullock DW, Damak S. Transgenic sheep. *Exp Biol Med* 1995;220:1-10.
10. Burdon TG, Wall RJ. Transgenic animals. *Reprod Dev* 1992;3:1-10.
11. Castro FO, Hernandez C, Herrera C, De la Fuente J. Transgenic animals. *Theriogenology* 1991;44:1-10.
12. Chan PJ, Kalugdan J. Noninvasive gene delivery. *Theriogenology* 1991;44:1-10.
13. Clements JE, Wall R, Zink MC, Rexroad CE. Transgenic animals. *Virology* 1994;200:1-10.

ving integration frequency, g transgenic livestock? One transgenic embryos before transgenic preimplantation with the polymerase chain d be greatly reduced. For 18 bovine embryos were enic calves and fetuses. If pipients would have been at this approach will not ed mouse embryos were ed and analyzed for the embryos had transgenes in ly upon microinjection. One of these arrays may d arrays segregate as after the one-cell stage, ne embryo is transgenic. ys but none integrate).

ore transfer is based on he preliminary results oth studies, transgenes ected into pronuclei of ured in the presence of at did not express the pression and because embryos containing ion process. However, s that expressed the at did not. Therefore, rapidly and have a nner cell mass (66). heme has merit.

s is inefficient. Over ure and useful new drive the technology comes increasingly rstanding of how ulatory pathways of

phenotypic characteristics that are to be altered to bring the fruits of this technology to animal agriculture. There is a serious need to transfer transgenic animal technology from a few practitioners to many more laboratories worldwide. Progress in the field will be limited as long as the capabilities to explore this potentially powerful tool is only in the hands of a few. To entice other scientists, the efficiency of producing transgenic farm animals will have to be improved. But the horizon looks bright. Many recently trained animal scientists are now equipped with the knowledge and technical skills needed to advance this technology.

REFERENCES

1. Behboodi E, Anderson GB, Horvat S, Medrano JF, Murray JD, Rowe JE. Microinjection of bovine embryos with a foreign gene and its detection at the blastocyst stage. *J Dairy Sci* 1993;76:3392-3399.
2. Bishop JO, Smith P. Mechanism of chromosomal integration of microinjected DNA. *Mol Biol Med* 1989;6:283-298.
3. Bondioli KR, Wall RJ. Positive selection of transgenic bovine embryos in culture. *Theriogenology* 1996;46:(abstract, this issue)
4. Brackett BG, Boranska W, Sawicki W, Koprowski H. Uptake of heterologous genome by mammalian spermatozoa and its transfer to ova through fertilization. *Proc Natl Acad Sci USA* 1971;68:353-357.
5. Brem G. Inheritance and tissue-specific expression of transgenes in rabbits and pigs. *Mol Reprod Dev* 1993;36:242-244.
6. Breslow JL. Transgenic mouse models of lipoprotein metabolism and atherosclerosis. *Proc Natl Acad Sci USA* 1993;90:8314-8318.
7. Brinster RL, Avarbock MR. Germline transmission of donor haplotype following spermatogonial transplantation. *Proc Natl Acad Sci USA* 1994;91:11303-11307.
8. Brinster RL, Sandgren EP, Behringer RR, Palmiter RD. No simple solution for making transgenic mice [letter]. *Cell* 1989;59:239-241.
9. Bullock DW, Damak S, Jay NP, Su H-Y, Barrell GK. Improved wool production from transgenic sheep expressing insulin-like growth factor I driven by a keratin promoter. In: Miller RH (ed). *Biotechnology's role in the genetic improvement of farm animals*. Beltsville Symposium XX. 1995;P8 (abstract).
10. Burdon TG, Wall RJ. Fate of microinjected genes in preimplantation mouse embryos. *Mol Reprod Dev* 1992;33:436-442.
11. Castro FO, Hernandez O, Oliver C, Solano R, Milanés C, Aguilar A, Perez A, d Armas R, Herrera C, De la Fuente J. Introduction of foreign DNA into the spermatozoa of farm animals. *Theriogenology* 1991;34:1099-1110.
12. Chan PJ, Kalugdan T, Su BC, Whitney EA, Perrott W, Tredway DR, King A. Sperm as a noninvasive gene delivery system for preimplantation embryos. *Fertil Steril* 1995;63:1121-1124.
13. Clements JE, Wall RJ, Narayan O, Hauer D, Schoborg R, Sheffer D, Powell A., Carruth LM, Zink MC, Rexroad CE. Development of transgenic sheep that express the visna virus envelope gene. *Virology* 1994;200:370-380.

14. Cousens C, Carver AS, Wilmut I, Colman A, Garner I, O'Neill GT. Use of PCR-based methods for selection of integrated transgenes in preimplantation embryos. *Mol Reprod Dev* 1994;39:384-391.
15. Dale TC, Krnacik M-J, Schmidhauser C, Yang CL, Bissell MJ, Rosen JM. High-level expression of the rat whey acidic protein gene is mediated by elements in the promoter and 3' untranslated region. *Mol Cell Biol* 1992;12:905-914.
16. Ebert KM, Schindler JES. Transgenic farm animals: Progress report. *Theriogenology* 1993;39:121-135.
17. Ellison AR, Wallace H, Al-Shawi R, Bishop JO. Different transmission rates of herpesvirus thymidine kinase reporter transgenes from founder male parents and male parents of subsequent generations. *Mol Reprod Devel* 1995;41:425-434.
18. Fabry ME. Transgenic animal models of sickle cell disease. *Experientia* 1993;49:28-36.
19. Fodor WL, Williams BL, Matis LA, Madri JA, Rollins SA, Knight JW, Velander W, Squinto SP. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. *Proc Natl Acad Sci USA* 1994;91:11153-11157.
20. Francolini M, Lavitrano M, Lamia CL, French D, Frati L, Cotelli F, Spadafora C. Evidence for nuclear internalization of exogenous DNA into mammalian sperm cells. *Mol Reprod Devel* 1993;34:133-139.
21. Fukuchi K-I, Ogburn CE, Smith AC, Kunkel DD, Furlong CE, Deeb SS, Noehlin D, Sumi SM, Martin GM. Transgenic animal models for Alzheimer's disease. *Ann NY Acad Sci* 1993;695:217-225.
22. Furth PA, Kerr DE, Wall RJ. Gene transfer by jet injection into differentiated tissues of living animals and in organ culture. *Molecular Biotechnology* 1995; in press.
23. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. *Proc Natl Acad Sci USA* 1994;91:9302-9306.
24. Gagné M, Pothier F, Sirard M-A. Effect of microinjection time during postfertilization S-phase on bovine embryonic development. *Mol Reprod Dev* 1995;41:184-194.
25. Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH. Genetic transformation of mouse embryos by microinjection of purified DNA. *Proc Natl Acad Sci USA* 1980;77:7380-7384.
26. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. *Science* 1995;268:1766-1769.
27. Grosveld F, van A, Greaves DR, Kollias. Position-independent, high-level expression of the human beta-globin gene in transgenic mice. *Cell* 1987;51:975-985.
28. Hammer RE, Pursel VG, Rexroad C, Wall RJ, Bolt DJ, Ebert KM, Palmiter RD, Brinster RL. Production of transgenic rabbits, sheep and pigs by microinjection. *Nature* 1985;315:680-683.
29. Haskell RE, Bowen RA. Efficient production of transgenic cattle by retroviral infection of early embryos. *Mol Reprod Dev* 1995;40:386-390.
30. Hill KG, Curry J, DeMayo FJ, Jones-Diller K, Slapak JR, Bondioli KR. Production of transgenic cattle by pronuclear injection. *Theriogenology* 1992;37:222 (abstract).
31. Hochi S, Minomiya T, Mizuno A, Homma M, Yuchi A. Fate of exogenous DNA carried into mouse eggs by spermatozoa. *Animal Biotechnology* 1990;1:25-30.
32. Horan R, Powell R, McQuaid S, Gannon F, Houghton JA. The association of foreign DNA with porcine spermatozoa. *Arch Androl* 1991;26:89-92.
33. Huang MTF. Gene targeting technology for creating transgenic models of lymphopoiesis. *Lab Anim Sci* 1993;43:156-159.
34. Huber MC, Bosch FX, Sippel A. gene transgenic mice are correlated. *Nucleic Acids Res* 1991;22:1197.
35. Hyttinen J-M, Peura T, Tolvanen S, Myohanen S, Janne J. Generation of sexed embryos produced *in vitro*.
36. Jaenisch R. Germ line integration of leukemia virus. *Proc Natl Acad Sci USA* 1995; in press.
37. Kerr DE, Furth PA, Powell AM. Ovine mammary gland and in vivo expression.
38. Lavitrano M, Camaioni A, Faz. for introducing foreign DNA in sperm cells. *Mol Reprod Devel* 1995;41:425-434.
39. Lavitrano M, French D, Zani M. DNA and sperm cells. *Mol Reprod Devel* 1995;41:425-434.
40. Li X, Faustman D. Use of donor isografts, allografts, and xenografts. *Proc Natl Acad Sci USA* 1994;91:11153-11157.
41. Lo D, Pursel V, Linton PJ, Sar. Expression of mouse IgA by transgenic mice. *Proc Natl Acad Sci USA* 1994;91:11153-11157.
42. McCarty KR, Kooyman DL, D. expression of human complement component deposition during development. *Proc Natl Acad Sci USA* 1992;89:69.
43. McKnight RA, Shamay A, Sar. can impart position-independent expression. *Natl Acad Sci USA* 1992;89:69.
44. Mehtali M, Munschy M, Al-Faraj. *in vivo* evaluation of anti-human retroviruses. *Proc Natl Acad Sci USA* 1992;89:69.
45. Minomiya T, Hirabayashi M. regions on human growth hormone. *Proc Natl Acad Sci USA* 1992;89:69.
46. Minomiya T, Hoshi S, Mizuno A. embryos carrying exogenous DNA. *Proc Natl Acad Sci USA* 1992;89:69.
47. Palmiter RD, Brinster RL. G. 60.
48. Palmiter RD, Brinster RL. H. develop from eggs microinjected. *Proc Natl Acad Sci USA* 1982;300:611-615.
49. Palmiter RD, Wilkie TM. Ch. unusual transgenic mouse production. *Proc Natl Acad Sci USA* 1982;300:611-615.
50. Petitclerc D, Attal J, Théron. Puissant C, Houdebine L-M. efficiency of expression vector. *J Biotechnol* 1995;3:1-7.
51. Pinkert CA, Stice SL, Embry. Monastersky GM, Robl JM. Washington, D.C. 1995; pp 7.

- Will GT. Use of PCR-based methods in embryos. *Mol Reprod Dev*
- J. Rosen JM. High-level expression in the promoter and 3'
- ... report. *Theriogenology*
- ... transmission rates of herpesvirus in sents and male parents of
- ... *Experientia* 1993;49:28-36.
- ... ight JW, Velander W, Squinto SP. Transgenic pig as a model for the *J Acad Sci USA* 1994;91:11153.
- ... elli F, Spadafora C. Evidence for sperm cells. *Mol Reprod Devel*
- ... Deeb SS, Nochlin D, Sumi SM. *Ann NY Acad Sci*
- ... o differer: tiated tissues of living press:
- ... Bujard H, Hennighausen L. Tetracycline-responsive promoter.
- ... during postfertilization S-phase 1-194.
- ... Genetic transformation of *J Acad Sci USA* 1980;77:7380-7384.
- ... H. Transcriptional activation 9.
- ... high-level expression of the 5.
- ... M, Palmiter RD, Brinster RL. *Nature* 1985;315:680-683.
- ... by retroviral infection of early
- ... oli KR. Production of 7:222 (abstract)
- ... ogenic DNA carried into
- ... sociation of foreign DNA with
- ... models of lymphopoiesis. *Lab*
34. Huber MC, Bosch FX, Sippel AE, Bonifer C. Chromosomal position effects in chicken lysozyme gene transgenic mice are correlated with suppression of DNase I hypersensitive site formation. *Nucleic Acids Res* 1994;22:4195-4201.
35. Hyttinen J-M, Peura T, Tolvanen M, Aalto J, Alhonen L, Sinervirta R, Halmekyto M, Myohanen S, Janne J. Generation of transgenic dairy cattle from transgene-analyzed and sexed embryos produced *in vitro*. *Biotechnology* 1994;12:606-608.
36. Jaenisch R. Germ line integration and mendelian transmission of the exogenous Moloney leukemia virus. *Proc Natl Acad Sci USA* 1976;73:1260-1264.
37. Kerr DE, Furth PA, Powell AM, Wall RJ. Expression of gene-gun injected plasmid DNA in the ovine mammary gland and in lymph nodes draining the injection site. *Animal Biotechnology* 1995; in press.
38. Lavitrano M, Camaioni A, Fazio VM, Dolci S, Farace MG, Spadafora C. Sperm cells as vectors for introducing foreign DNA into eggs: genetic transformation of mice. *Cell* 1989;57:717-723.
39. Lavitrano M, French D, Zani M, Frati L, Spadafora C. The interaction between exogenous DNA and sperm cells. *Mol Reprod Devel* 1992;31:161-169.
40. Li X, Faustman D. Use of donor b2-microglobulin-deficient transgenic mouse liver cells for isografts, allografts, and xenografts. *Transplantation* 1993;55:940-946.
41. Lo D, Pursel V, Linton PJ, Sandgren E, Behringer R, Rexroad C, Palmiter R.D., Brinster RL. Expression of mouse IgA by transgenic mice, pigs and sheep. *Eur J Immunol* 1991;21:1001-1006.
42. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS, Platt JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. *Transplantation* 1995;59:1177-1182.
43. McKnight RA, Shamay A, Sankaran L, Wall RJ, Hennighausen L. Matrix-attachment regions can impart position-independent regulation of a tissue-specific gene in transgenic mice. *Proc Natl Acad Sci USA* 1992;89:6943-6947.
44. Mehtali M, Munsch M, Ali-Hadji D, Kieny MP. A novel transgenic mouse model for the *in vivo* evaluation of anti-human immunodeficiency virus type 1 drugs. *AIDS Res Hum Retroviruses* 1992;8:1959-1965.
45. Ninomiya T, Hirabayashi M, Sagara J, Yuki A. Functions of milk protein gene 5' flanking regions on human growth hormone gene. *Mol Reprod Devel* 1994;37:276-283.
46. Ninomiya T, Hoshi S, Mizuno A, Nagao M, Yuki A. Selection of mouse preimplantation embryos carrying exogenous DNA by polymerase chain reaction. *Mol Reprod Devel* 1989;1:242-248.
47. Palmiter RD, Brinster RL. Germline transformation of mice. *Ann Rev of Genetics* 1986;20:3-60.
48. Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. *Nature* 1982;300:611-615.
49. Palmiter RD, Wilkie TM, Chen HY, Brinster RL. Transmission distortion and mosaicism in an unusual transgenic mouse pedigree. *Cell* 1984;36:869-877.
50. Petitclerc D, Attal J, Theron MC, Bearzotti M, Bolifraud P, Kann G, Stinnakre M-G, Pointu H, Puissant C, Houdebine L-M. The effect of various introns and transcription terminators on the efficiency of expression vectors in various cultured cell lines and in the mammary gland of transgenic mice. *J Biotechnol* 1995;40:169-178.
51. Pinkert CA, Stice SL. Embryonic Stem cell strategies: beyond the mouse model. In: Monastersky GM, Robl JM (eds). *Strategies in transgenic animal science*. ASM Press, Washington, D.C. 1995; pp 73-88.

52. Pursel VG, Hammer RE, Bolt DJ, Palmiter RD, Brinster RL. Integration, expression and germ-line transmission of growth-related genes in pigs. *J Reprod Fertil Suppl* 1990;41:77-87.
53. Pursel VG, Rexroad CE, Jr. Status of research with transgenic farm animals. *J Anim Sci* 1993;71 Suppl. 3:10-19.
54. Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. A potential approach for preventing xenograft rejection. *Transplantation* 1995;59:1325-1333.
55. Rothnagel JA, Greenhalgh DA, Wang X-J, Sellheyer K, Bickenbach JR, Dominey AM, Roop DR. Transgenic models of skin diseases. *Arch Dermatol* 1993;129:1430-1436.
56. Sato M, Iwase R, Kasai K, Tada N. Direct injection of foreign DNA into mouse testis as a possible alternative of sperm-mediated gene transfer. *Anim Biotechnol* 1994;5:19-31.
57. Schellander K, Peli J, Schmoll F, Brem G. Artificial insemination in cattle with DNA-treated sperm. *Animal Biotechnology* 1995;41-50.
58. Shamay A, Solinas S, Pursel VG, McKnight RA, Alexander L, Beattie C, Hennighausen L, Wall RJ. Production of the mouse whey acidic protein in transgenic pigs during lactation. *J Anim Sci* 1991;69:4552-4562.
59. Swanson ME, Martin MJ, O'Donnell JK, Hoover K, Lago W, Huntress V, Parsons CT, Pinkert CA, Pilder S, Logan JS. Production of functional human hemoglobin in transgenic swine. *Bio/technology* 1992;10:557-559.
60. Tada N, Sato M, Hayashi K, Kasai K, Ogawa S. In vitro selection of transgenic mouse embryos in the presence of G-418. *Transgenics* 1995;1:535-540.
61. Thompson TC, Long LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transgenic models for the study of prostate cancer. *Cancer* 1993;71 Suppl. 1165-1171.
62. Wagner SD, Williams GT, Larson T, Neuberger MS, Kitamura D, Rajewsky K, Xian J, Brüggemann M. Antibodies generated from human immunoglobulin miniloci in transgenic mice. *Nucleic Acids Res* 1994;22:1389-1393.
63. Wall RJ. Modification of milk composition in transgenic animals. In: Miller RH (ed). *Biotechnology's role in the genetic improvement of farm animals*. Beltsville Symposium XX, 1995; in press.
64. Wall RJ, Hawk HW, Nel N. Making transgenic livestock: genetic engineering on a large scale. *J Cell Biochem* 1992;49:113-120.
65. Wall RJ, Pursel VG, Hammer RE, Brinster RL. Development of porcine ova that were centrifuged to permit visualization of pronuclei and nuclei. *Biol Reprod* 1985;32:645-651.
66. Wall RJ, Seidel G, Jr. Transgenic farm animals--A critical analysis. *Theriogenology* 1992;38:337-357.
67. Weidle UH, Lenz H, Brem G. Genes encoding a mouse monoclonal antibody are expressed in transgenic mice, rabbits and pigs. *Gene* 1991;98:185-191.
68. Zani M, Lavitrano M, French D, Lulli V, Maione B, Sperandio S, Spadafora C. The mechanism of binding of exogenous DNA to sperm cells: factors controlling the DNA uptake. *Exp Cell Res* 1995;217:57-64.

AMINO ACID
MOUSE EM
PRE

Depar
51

Several nonessential
embryos *in vitro* and in
surrogate mothers. The be-
of them by embryos via tra-
of the transport systems is
degradation of mRNAs and
amino acid transport pro-
transgenic experiments fu-
needed for normal pre- and

1. Introduction and Scope

Since the advent of
years ago [1], amino acids
period to clearly beneficial
amino acid transport syst-
superfluous. We have, in
mechanisms by which an-

In this review we
nonessential amino acids
development. Moreover,
system activities may be
nonessential amino acids
beneficial during the pre-
develop from preimplanta-
however, not considering
their presence in the medi-
our discussion primarily to
effects of amino acids on
There is, however, incor-
regulation of their expres-
most prudent to use the
amino acids may benefit

Acknowledgment
Work in the author's

Theriogenology 45:69-80, 1996.
© 1996 by Elsevier Science Inc.
655 Avenue of the Americas, New York, NY 10010.

CLIN. AND EXPER. HYPERTENSION, 17(4), 593-605 (1995)

REVIEW

TRANSGENIC ANIMALS AS MODELS FOR HUMAN DISEASE

Juergen Wagner, Felix Thiele, Detlev Ganten

German Institute for High Blood Pressure Research and Max Delbrück Center for Molecular
Medicine, Berlin, Germany

Keywords: Transgenic animals, human disease, genetics, cardiovascular disease, oncology,
immunology, toxicology, Alzheimer's disease, embryo development

Abstract

Since its first description in 1981 (1), transgenic technology has greatly influenced the focus
and direction pace of biomedical research. Introduction of foreign DNA into the genome of
animals by microinjection into fertilized oocytes is now used in almost every field of research
spanning from oncology, immunology and neurology to cardiovascular medicine. The ability

Address for correspondence:

Dr. Juergen Wagner
Max Delbrück Center for Molecular Medicine
Franz-Gross-Haus/134D
Willbergstraße 50
13122 Berlin
Germany

to integrate genes in the germline and their successful expression in the host provides an opportunity to study the role of a certain gene in the initiation and propagation of disease. Transgenic methodology serves as the link between molecular biology, introducing *in vitro* a defined genetic modification and whole animal physiology, with the resulting *in vivo* alteration of body function. This potential has been exploited to study the pathophysiological role of human genes. Transgenic animals have been used to study aspects of tumor development, immune regulation, cardiovascular development and atherosclerosis. These studies have provided new insights into the genetic origin of certain diseases and have improved our understanding of pathological processes on the cellular level. As a future goal, these studies may also serve the development of new diagnostic tools or novel therapeutic strategies such as gene therapy.

Introduction

Our understanding of body function in health and disease has been advanced in the past primarily by the use of animal models for human disease. However, to establish a relationship between the regulation of a certain gene and a complex disease process has been difficult. The expression of a foreign gene creates a defined genetic defect, which allows to closely correlate the effect of this gene to a physiological trait.

Studies on the regulation of gene expression and gene function in humans are strongly limited due to ethical reasons. Expression of human transgenes in animals therefore is an elegant way to obviate these difficulties. Experiments using transgenic animals can be divided into four categories: 1) Studies on gene regulation: which include the expression of only the regulatory elements of a gene such as the promoter region in transgenic animals. The promoter region of a gene is connected to a reporter gene which is easily detectable. Such studies using the promoter region are of use in the analysis the regulatory elements for tissue-specific expression and identification of cis-acting factors controlling gene transcription. 2) Investigation of the function of a gene product: Here, the gene of interest is under control of either the natural homologous promoter or a heterologous one which directs expression to specific cells and tissues. Additionally, mutants of the gene of interest may be introduced for

analysis of specific biochemical properties. 3) *In vivo* immortalization of cells: this is accomplished e.g. by fusion of a gene promoter region to a SV 40 large T antigen. The immortalized cell lines are then isolated for *in vitro* analysis. Finally 4) expression of proteins in mammary gland tissue in order to obtain large quantities of secretory protein within the milk.

Transgenic technology was originally developed in the mouse and, therefore, most transgenic studies are performed in this species. The mouse model provides several advantages such as comparatively numerous offspring with short generation times and well-known genetics. For specific research questions, however, other species have been used such as rat, sheep, rabbit, goat and zebrafish (2-5). In cardiovascular research rats have been the animals of choice to study cardiovascular function. They are suitable for pharmacological tests and have provided animal models for hypertension, cardiac and renal disease.

The most widely used technique applied for transgenic production is micromanipulation of fertilized oocytes from superovulated donor animals and microinjection of DNA into the pronucleus (1,6). The DNA-injected eggs are reimplanted into pseudopregnant foster mothers and the offspring are then analysed for the presence of the foreign DNA in the genome. This technique is basically common to all animal species where this technology has been applied. Time schedule, hormone treatment and operating procedure, however, require adjustment to the respective species. Whereas microinjection aims at implantation of foreign genomic material into the germline, different techniques have been developed to insert DNA into *somatic* cells (7-10). This implies transgenesis in cells which are not part of the germline and, therefore, a genetic alteration can not be propagated to the offspring. These techniques often aim at gene therapeutic approaches where a defective gene can be replaced in function at some time in the ontogeny.

Three methodological approaches have been used to generate transgenic animals: i) injection of DNA into the pronucleus of fertilized oocytes as described above. ii) homologous recombination in embryonic stem cells of mice (11) and iii) retroviral infection of preimplantative blastocysts (12). At present, research efforts are focused on the first two techniques which represent two sides of a coin. The "knock out" approach achieved with homologous recombination yields a "loss-of-function" study, in contrast to the "gain-of-

function" approach which is used in microinjection causing overexpression of a gene. "Loss-of-function" is a tool to analyse the function of a gene by functional interruption and is achieved by inserting a disruptive sequence *in vitro*. The endogenous gene is replaced with the mutated gene by homologous recombination in the stem cell. Despite the precision of this method, functional conclusions are not easily drawn from such experiments. For example, gene "knock-outs", especially of transcription factors, have often demonstrated no apparent phenotype due to the functional redundancy of cell and gene regulatory systems. Other gene disruptions have precluded extensive analysis due to embryonic lethality. Studies using partial "loss-of-function"-mutants or double knock outs are under way to obviate these difficulties (13). Thus far, embryonic stem cell technology has only been successful in mice, however, the need to generate rat embryonic stem cells has been recognised for physiological and pharmacological investigations.

Homologous recombination allows replacement of a the native gene by a mutant which can be analysed in the natural chromosomal environment, which affects gene expression and regulation. In contrast, transgenesis by micorinjection occurs by random insertion into the genome without control of copy numbers of DNA integrated. To achieve a reproducible gene integration, locus control regions or matrix attachment regions have been used as control elements to direct transgene integration (14-17). Another successful strategy has been not to inject the transgene alone but rather large DNA constructs such as yeast artificial chromosomes (18-19), in order to control the "environment" of the transgene. These techniques will in the future redefine the transgenic methodology and possibly other newly developed strategies for somatic transgenesis. Progress in this field can not be separated from gene therapeutic approaches, where a foreign gene will be transferred into somatic cells. A vast number of different *in vitro* and *in vivo* strategies exists for gene transfer. *In vitro* strategies use host cells that are isolated from the body, grown, stably transfected with a transgene and then reimplanted (10). *In vivo* studies directly apply DNA to the host either by direct injection into the tissue of interest, by liposomal transfection, by retroviral or adenoviral infection (8,9) or by receptor-mediated uptake e.g. by via the transferrin receptor. A detailed description of these technologies, however, is beyond the scope of this article.

Transgenic animals in cardiovascular disease

The cardiovascular system has been the focus of interest for transgenic research due to the high cardiovascular morbidity and mortality in industrialized societies. Transgenic animals have been generated for almost every aspect of cardiovascular research from hypertension to formation of myocardial tumors. The candidate gene approach has been used to study the effects of gene products of hormones which are known to be involved in blood pressure regulation and which are supposed to play a role in the pathogenesis of hypertension. Other risk factors of cardiovascular disease such as atherosclerosis or hemostatic mechanisms have been investigated by transgenic techniques.

Candidate gene approach/neurohormonal studies

The regulation of cardiovascular function is complex and depends on many factors which interact in a defined spatial and temporal pattern. It is therefore difficult to assign a particular phenotype or functional parameter to a certain gene. Transgenic introduction of a gene into an organism does allow to define the contribution of a certain gene to the physiology or pathophysiology of cardiovascular function. Due to the multitude of hormones, regulatory peptides, cell signalling pathways etc., research has focused on the role of candidate genes. These are genes, which are known to be involved in cardiovascular regulation and, therefore, likely to play a role in dysfunction of the heart or the vascular wall as in hypertension. Since the expression of the transgene in animals is the only difference to transgene-negative control animals, a change in cardiovascular function can be correlated to the presence of the transgene.

The precursor of *arginine vasopressin*, *preproarginine vasopressin*, which is under control of the metallothionein promoter has been expressed in transgenic mice resulting in chronically elevated levels of vasopressin in the plasma (20). Increased levels of vasopressin were present in the plasma elevating serum osmolality to levels corresponding to mild nephrogenic diabetes insipidus. *Atrial natriuretic peptide* which is known to reduce blood pressure and to induce a

marked natriuresis has been expressed in mice to study the effects of chronically elevated ANP levels on cardiovascular function. Use of the heterologous mouse promoter transthyretin resulted in a ten-fold elevation of immunoreactive plasma ANP and significantly lowered blood pressure without altering plasma electrolyte balance (21).

Transgenic animals have also been generated in hypertension research. Besides the known influence of environmental factors on the development of high blood pressure, hypertension has a strong genetic background (22,23). Therefore, candidate genes of hypertension such as the components of the *renin-angiotensin system* have been studied in detail. This system is a major regulator of blood pressure and of sodium- and volume homeostasis. Renin genes of different species, as well as its substrate angiotensinogen, have been introduced into transgenic mice (24-27). Transgenic mice expressing both the rat or human renin and angiotensinogen gene developed elevated blood pressure levels (27,28). However, rats, as opposed to mice, have attracted much interest in the field of research, since they are more suitable for hemodynamic, pharmacological and functional studies. Rats with hereditary hypertension, such as spontaneously hypertensive rats, have been used as a model for primary human hypertension. Expression of the mouse renin-2-gene in transgenic rats has led to fulminant hypertension with values in the range of 220 mmHg systolic in heterozygous animals (3). Unexpectedly, despite the presence of an additional renin gene, these rats exhibit a low plasma renin activity, corresponding to low renin hypertension syndromes in humans. Transgenic rats with the human renin and angiotensinogen gene have also been generated which maintain the species-specificity of the human renin-substrate reaction (4).

Cardiovascular aspects can also be demonstrated in transgenic mice overexpressing *growth hormone* (29,30). Excess growth hormone in humans causes acromegaly and gigantism. Patients suffering from this disease frequently develop hypertension, although growth hormone by itself is not hypertensinogenic. Overexpression of a metallothionein-fusion gene in mice did not significantly raise blood pressure, but the vascular wall-to-lumen ratio was significantly altered in mesenteric arteries. The increase in wall thickness in these arteries may elevate peripheral resistance and thus contribute to the hypertensive blood pressure levels in acromegalic patients. However, the multifocal expression of growth hormone has also a

number of other effects resulting in progressive glomerulosclerosis after induction of mesangial cell growth. (30)

In addition to hypertension, other risk factors of cardiovascular disease such as atherosclerosis have been investigated: Lipoproteins are the macromolecular transporters of non-polar lipids. The major high density lipoprotein (HDL) associated apolipoprotein is *apolipoprotein AI*. Plasma HDL concentrations as well as apoAI levels have been shown to be inversely correlated to the development of premature coronary heart disease. As its major apolipoprotein constituent, apoAI plays a central role in HDL assembly. The human apoAI gene was transferred into the atherosclerosis susceptible inbred mouse strain C57BL/6. This transgenic lead to a 2-fold increase in apoAI and HDL. Similarly, apolipoprotein E was expressed in transgenic mice (32). Although these mice were fed a high fat diet, they were markedly protected from atherosclerotic plaques. In other experiments, high levels of the *low density lipoprotein (LDL) receptor* was expressed using a receptor cDNA under the control of a metallothionein promoter. These mice cleared LDL from blood 8-times faster than normally. The transfer of LDL receptors to patients with known genetic LDL receptor defects as in familial hypercholesterolemia may be an approach to replace defective receptor function (33).

Transgenic animals in pulmonary disease

Most animal models which are used to mimic human disease are based on lesions which are applied to the adult animal and then the course of disease or the effect of treatment is analysed over time. Whereas animal models applicable to chronic and degenerative disease processes is less frequent developed. New animal models for chronic human disease may be generated by transgenic animals either by overexpression and excess function of a particular gene or by disruption of a functional gene. The success of these approaches depends on the extent to which a singular gene is indeed responsible for a disease. The investigation of *cystic fibrosis* the most common autosomal inherited disease, is a paradigm for these problems. The defective gene in cystic fibrosis patients has been identified as *Cfr*, which encodes an ion channel at the cell membrane. By homologous recombination, several groups succeeded to

disrupt the *Cfr* gene (34-36). All animal lines developed symptoms of cystic fibrosis. Although all these experiments created null mutations, the time course and the pattern of tissue involvement differed between the lines. These null mutation mice may be used for further studies on the *Cfr* gene, by introducing mutations of the *Cfr* gene via the transgenic approach. Comparison of the different clinically important mutations compromising the *Cfr* gene may clarify the tissue specific pattern of tissue involvement. Beyond that, these mice are excellent models to develop gene therapeutic strategies. Somatic transgenesis by liposomal transfection led to expression of a functional *Cfr* gene in the lung of these transgenic mice with the disrupted ion channel. (7). Gene therapeutical trials are now underway in humans with cystic fibrosis to apply the an intact *Cfr* gene supplementing the defective non-functional *Cfr* gene.

Transgenic animals in neurodegenerative disorders

As for chronic lung disease, transgenic methodology is being used to generate animal models which represent important aspects of human neurodegenerative disorders. The focus of interest has been *Alzheimer's disease*, where beta-amyloid, derived from the amyloid precursor protein, is chronically deposited in senile plaques and along vessel walls. In some forms of familial Alzheimer's disease, mutations of the amyloid precursor protein have been identified to be responsible for the development of the disease. Expression of the amyloid precursor protein in transgenic mice has not led to a distinctive Alzheimer's disease phenotype in the brain of these animals, however, a carboxyterminal fragment of the amyloid protein precursor causes neurodegeneration *in vivo* (37). Whether this closely correlates to Alzheimer's disease in humans is not clear and further studies aimed at overexpression of other components of the senile plaques such as the microtubule-associated protein *tau* are under way to generate an animal model for the human disease.

Transgenic animals in oncology or immunology

In these fields, most of the research employing transgenic technology is focused on fundamental studies rather than clinical disease. Several studies are being performed to

clarify the regulation of oncogenes. In particular, how they are activated and by which pathways these oncogenes exert their carcinogenic potential. Transgenic animals have been used as specific research tools to study the different steps in tumor development leading to a better understanding of the tumor-host interaction, tumor growth and angiogenesis and metastatic seeding. The analysis of these processes may lead to new therapeutic strategies, which could interrupt tumor development at the different stages. Similarly, the understanding of the immune system, the cytokine network and the host versus graft reaction in transplantation have been enhanced by transgenic approaches (38). The interaction of the cytokine network with antibody formation and B cell activity has been studied by "knock out" experiments. Gene targeting was used to disrupt genes involved in B and T cell differentiation (38,39). The role of cytokines and of differentiation factors in autoimmune and inflammatory disease has been investigated in several transgenic models. Overexpression of *human tumour necrosis factor alpha* in transgenic mice led to the development of chronic arthritis and systemic tumor necrosis factor-mediated disease (40). As a sign of chronic arthritis, accumulation of polymorphnuclear cells, synovial thickening and finally synovial hyperplasia and pannus, eroding the cartilage was observed. Similarly "knock out" of *transforming factor beta* led to chronic and diffuse inflammation (41). How these experiments truly represent human syndromes of chronic inflammation remains to be elucidated, but they allow the investigation of the regulation of inflammatory processes.

Concluding remarks

Transgenic methodology has so rapidly developed that inclusion of all relevant data and publications is beyond the scope of this manuscript. However, it has been shown that transgenic methodology has spread into every field of biomedical research. Transgenic animals are being used to create new models for human disease, i) by generation of animal models which resemble the human condition as close as possible and ii) by in-detail analysis of the pathogenesis of human diseases under *in vivo* conditions. The further refinement of this technology from simple injection of foreign DNA into an oocyte to expression of large chromosomal regions and to the technique of embryonic stem cell manipulation underscores the fact that this technology is still in development.

Transgenic methodology, however, can not be considered in isolation: It is rather part of a major advancement gene technology has provided, extending into the fields of cell biology and molecular genetics. For examples, novel strategies in molecular genetics allow to identify the causative genes for disease and pathophysiological processes. In return, these genes can then be tested in transgenic animals on the functional and cellular level. In the future, these technologies can act in concert to develop new therapeutic strategies for human diseases and are therefore of interest for clinical applications. The methodological expansion, however, requires collaborative efforts of scientists and transfer of know-how between specialised laboratories more than ever.

REFERENCES

1. Gordon, J.W. & Ruddle, F.H. Integration and stable germ line transmission of genes injected into the mouse pronucleus. *Science* 1981; 214: 1244-1246.
2. Hammer, R.E., Maika, S.D., Richardson, J.A., Tang, J. & Taurog, J.D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human b2m: An animal model of HLA-B27-associated human disorders. *Cell* 1990; 63: 1099-1112.
3. Mullins, J.J., Peters, J. & Ganten, D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. *Nature* 1990; 344: 541-544.
4. Ganten, D., Wagner, J., Zeh, K., Bader, M., Michel, J.-B., Paul, M., Zimmermann, F., Ruf, P., Hilgenfeldt, U., Ganten, U., Kaling, M., Bachmann, S., Fukamizu, A., Mullins, J.J. & Murakami, K. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. *Proc Natl Acad Sci USA* 1992; 89: 7806-7810.
5. Hochi, S.-I., Ninomiya, T., Waga-Homma, M., Sagara, J. & Yuki, A. Secretion of bovine a-lactalbumin into the milk of transgenic rats. *Mol Reprod Develop* 1992; 33: 160-164.
6. Hogan, B., Costantini, F., & Lacy, E. Manipulating the mouse embryo, Cold Spring Harbor, New York 11724: Cold Spring Harbor Laboratory, 1986.
7. Hyde, S.C., Gill, D.R., Higgings, C.F. & Trezise, A.E.O. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. *Nature* 1993; 362: 250-255.
8. Nabel, E.G., Plautz, G. & Nabel, G.J. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. *Science* 1990; 249: 1285-1288.
9. Zhu, N., Liggitt, D., Liu, Y. & Debs, R. Systemic gene expression after intravenous DNA delivery into adult mice. *Science* 1993; 261: 209-211.
10. Mulligan, R.C. The basic science of gene therapy. *Science* 1993; 260: 926-932.

11. Capecchi, M.R. Altering the genome by homologous recombination. *Science* 1989; 244: 1288-1292.
12. Jaenisch, R., Jahner, D., Nobis, P., Simon, T., Lohler, J., Harbers, K. & Grotkopp, D. Chromosomal position and advance of retroviral genomes inserted into germ line of mice. *Cell* 1981; 24: 519.
13. Hasty, P., Ramirez-Solis, R., Krumlauf, R. & Bradley, A. Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. *Nature* 1991; 350: 243-246.
14. Grosveld, F., Blom van Assendelft, G., Greaves, D. & Kollias, G. Position-independent, high-level expression of the human β -globin gene in transgenic mice. *Cell* 1987; 51: 975-986.
15. Greaves, D., Wilson, F., Lang, G. & Kioussis, D. Human CD23-flanking sequences confer high-level T cell specific, position-independent expression in transgenic mice. *Cell* 1989; 51: 979-986.
16. Izzaurralde, E., Mirkovitch, J. & Lacmli, U.K. Interaction of DNA with nuclear scaffolds *in vitro*. *J.Mol.Biol.* 1988; 200: 111-125.
17. Stief, A., Winter, D.M., Stratling, W.H. & Sippel, A.E. A nuclear DNA attachment element mediates elevated and position-independent gene activity. *Nature* 1989; 341: 343-345.
18. Burke, D., Carle, G. & Olson, M. Cloning of large segments of exogenous DNA into yeast by means of artificial chromosome vectors. *Science* 1987; 236: 808-811.
19. Schedle, A., Beerman, F., Thies, E., Montoliu, L., Kelsey, G. & Schutz, G. Transgenic mice generated by pronuclear injection of a yeast artificial chromosome. *Nucleic Acids Res.* 1992; 20: 3073-3077.
20. Habener, J.F., Cwikel, B.J., Hermann, H., Hammer, R.E., Palmiter, R.D. & Brinster, R.L. Metallothionein-vasopressin fusion gene expression in transgenic mice. *J Biol Chem* 1989; 264: 18844-18852.
21. Steinhilper, M.E., Cochrane, K.L. & Field, L.J. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. *Hypertension* 1990; 16: 301-307.
22. Jeunemaitre, X., Soubrier, F., Kotelevtsev, Y.V., Lifton, R.P., Williams, C.S., Charru, A., Hunt, S.C., Hopkins, P.N., Williams, R.R., Lalouel, J. & Corvol, P. Molecular basis of human hypertension: role of angiotensinogen. *Cell* 1992; 71: 169-180.
23. Hilbert, P., Lindpaintner, K., Beckmann, J.S., Serikawa, T., Soubrier, F., Dubay, C., Cartwright, P., DeGouyon, B., Julier, C., Takahasi, S., Vincent, M., Ganten, D., Georges, M. & Lathrop, G.M. Chromosomal mapping of two genetic loci associated with blood-pressure regulation in hereditary hypertensive rats. *Nature* 1991; 353: 521-529.
24. Wagner, J., Zeh, K. & Paul, M. Transgenic rats in hypertension research. *J Hypertens* 1992; 10: 601-605.
25. Kimura, S., Mullins, J.J., Bunnemann, B., Metzger, R., Hilgenfeldt, U., Zimmermann, F., Jacob, H., Fuxe, K., Ganten, D. & Kaling, M. High blood pressure in transgenic mice carrying the rat angiotensinogen gene. *EMBO J* 1992; 11: 821-827.

26. Takahashi, S., Fukamizu, A., Hasegawa, T., Yokoyama, M., Nomura, T., Katsuki, M. & Murakami, K. Expression of the human angiotensinogen gene in transgenic mice and transfected cells. *Biochem Biophys Res Commun* 1991; 180: 1103-1109.
27. Ohkubo, H., Kawakami, H., Kakehi, Y., Takumi, T., Arai, H., Yokota, Y., Iwai, M., Tanabe, Y., Masu, M., Hata, J., Iwao, H., Okamoto, H., Yokoyama, M., Nomura, T., Katsuki, M. & Nakanishi, S. Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. *Proc Natl Acad Sci USA* 1990; 87: 5153-5157.
28. Fukamizu, A., Sugimura, K., Takimoto, E., Sugiyama, F., Seo, M.S., Takahashi, S., Hatae, T., Kajiwara, N., Yagami, K. & Murakami, K. Chimeric renin angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. *J Biol Chem* 1993; 268: 11617-11621.
29. Dilley, R.J. & Schwartz, S.M. Vascular remodeling in the growth hormone transgenic mouse. *Circ Res* 1989; 65: 1233-1240.
30. Doi, T., Striker, L.J., Gibson, C.C., Agodoa, L.Y., Brinster, R.L. & Striker, G.E. Glomerular lesion in mice transgenic for growth hormone and insulin-like growth factor-I: relationship between increased glomerular size and mesangial sclerosis. *Am J Pathol* 1990; 137: 541-552.
31. Swanson, M.B., Hughes, T.E., St.Denny, I., France, D.S., Paterniti, J.R., Tapparelli, C., Geller, P. & Burki, K. High level expression of human apolipoprotein A-I in transgenic rat raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-I. *Transgenic Research* 1992; 1: 142-147.
32. Shimano, H., Yamada, N., Katsuki, M., Shimada, M., Gotoda, T., Harada, K., Murase, T., Fukazawa, C., Takaku, F. & Yazaki, Y. Overexpression of apolipoprotein B in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia. *Proc Natl Acad Sci USA* 1992; 89: 1750-1754.
33. Hofmann, S.L., Russell, D.W., Brown, M.S., Goldstein, J.L. & Hammer, R.E. Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice. *Science* 1988; 239: 1277-1281.
34. Snouwaert, J.M., Brigman, K.K., Latour, A.M., Malouf, N.N., Boucher, R.C., Smithies, O. & Koller, B.H. An animal model for cystic fibrosis made by gene targeting. *Science* 1992; 257: 1083-1088.
35. Dorin, J.R., Dickinson, P., Alton, E.W.F.W., Smith, S.N., Geddes, D.M., Stevenson, B.J., Kimber, W.L., Fleming, S., Clarke, A.R., Hooper, M.L., Anderson, L., Beddington, R.S. & Proteous, D.J. Cystic fibrosis in the mouse by targeted insertional mutagenesis. *Nature* 1992; 359: 211-215.
36. College, W.H., Ratcliff, R., Foster, D., Williamson, R. & Evans, M.J. Cystic fibrosis mouse with intestinal obstruction. *Lancet* 1992; 340: 680.
37. Neve, R.L., Kozlowski, M.R., Kammerscheidt, A., & Hohmann, C. The carboxyterminal fragment of the Alzheimer amyloid protein precursor causes neurodegeneration *in vivo*. In: *Transgenic animals as model system for human diseases*, eds. E.F. Wagner & F. Theuring, Berlin: Springer-Verlag, 1993; 57-72.

38. Parham, P. Some savage cuts in defence. *Nature* 1990; 344: 709-711.
39. Rajewsky, K. A phenotype or not: targeting genes in the immune system. *Science* 1992; 256: 483
40. Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslari, E., Kioussis, D. & Kollias, G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. *EMBO J* 1991; 10: 4025-4031.
41. Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., Annunziata, N. & Doetschman, T. Targeted disruption of the mouse transforming growth factor- β 1 gene results in multifocal inflammatory disease. *Nature* 1992; 359: 693-699.

Submitted: 11/1/94

Accepted: 12/9/94